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INTRODUCTION 
Acute kidney injury is the new consensus term for acute renal 
failure.
1
Acute kidney injury (AKI) is a syndrome that takes on different 
forms. The severity of this syndrome is also variable. It refers to a clinical 
syndrome characterised by a rapid (hours to days) decrease in renal 
excretory function, with the accumulation of products of nitrogen 
metabolism such as creatinine and urea and other clinically unmeasured 
waste products. Other common clinical and laboratory manifestations 
include decreased urine output (not always present), accumulation of 
metabolic acids, and increased potassium and phosphate 
concentrations.
2,3,4 
AKI is the most common renal emergency in India. Around 1.5% 
of patients that are admitted to hospitals are referred to nephrology units 
for acute kidney injury.
5,6,7
 Worldwide incidence of AKI is variable,
8,9 
and 
even more among the developed and the developing countries.
10
 The 
incidence of AKI varies greatly. It depends on the setting in which kidney 
injury occurs.
11 
The data that is available regarding the overall epidemiology of 
AKI is very limited. However it is very important to know the 
epidemiology and clinical features of AKI, so as to execute adequate 
means for tackling the problem and to boost preventive strategies.
12
 
Statistics which are based on a referral to a renal replacement 
therapy unit suggest that the problem is more common in the tropics.
13 
Despite advances in renal replacement therapy, the mortality in 
AKI remained more or less same in the last five decades.  Several factors 
redound to this persistently high mortality. They include reasons such as a 
more elderly population with AKI and the fact that patients with more 
severe ailments survive long enough to develop kidney injury.
14
 Recent 
data have shown that even small changes in renal function are associated 
with a substantial increase in mortality
.14,15
 
The etiological spectrum of AKI is notably different between 
developing and developed nations. It is related to environmental, social 
and economic circumstances. Sepsis, surgery and trauma are the most 
common causes of AKI in developed countries. In developing countries, 
acute diarrheal diseases and tropical diseases still prevail.
16
 The aetiology, 
course, and outcome of AKI differ in various parts of India
5,6,17
  
In 2004, the Acute Dialysis Quality Initiative (ADQI)
1,18-23
 group, 
comprising experts in the fields of nephrology and critical care medicine, 
published the RIFLE classification. This was a new consensus and 
evidence-based definition for AKI.
1
 The RIFLE classification defines 
three grades of severity and two clinical outcomes of acute kidney injury. 
The three grades of severity (Risk, Injury and Failure) based on changes 
to serum creatinine and urine output. The two clinical outcomes are Loss 
and End-stage. In 2007, a modified version of the RIFLE criteria was 
published by the AKI Network (AKIN), an international collaboration of 
nephrologists and intensivists, known as the AKIN criteria.
24 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
DEFINITION AND CLASSIFICATION 
Acute kidney injury (AKI) is a protean syndrome of varied 
severity. It is characterized by a rapid (hours to weeks) decline in the 
glomerular filtration rate (GFR) and retention of nitrogenous waste 
products such as blood urea nitrogen (BUN) and creatinine.
2,3
In recent 
years, it was realised that the time-honoured term acute renal failure 
(ARF) does not sufficiently describe the dynamic process propagating 
across initiation, maintenance, and recovery phases. Each phase may be 
of changing duration and severity.  
The proposed alternative term acute kidney injury has much to 
recommend it. It better captures the diverse nature of this syndrome.  
Hence it has entered into widespread clinical use. 
Historically, patients with AKI have been classified as being non-
oliguric (urine output >400 mL/day), oliguric (urinary out-put <400 
mL/day), or anuric (urinary output <100 mL/day).
25
 Lower levels of 
urinary output reflects a more severe initial injury. It has implications for 
volume overload and electrolyte disturbances. It also has prognostic 
significance. However, therapeutic manipulation of the urine output does 
not change this bad prognostic association. 
For purposes of diagnosis and management, AKI has been divided 
into three categories
26 
1. Diseases characterized by renal hypoperfusion in which the 
integrity of renal parenchymal tissue is preserved (prerenal AKI), 
2. Diseases involving renal parenchymal tissue (intrinsic AKI),  
3. Diseases associated with acute obstruction of the urinary tract 
(postrenal AKI). 
Most cases of acute intrinsic AKI are caused by ischemia or nephrotoxins 
and are classically associated with ATN. 
AKI may occur in with either a previously normal renal function or 
as an acute deterioration in function in the presence chronic kidney 
disease. 
The etiology and outcome of AKI is heavily influenced by the 
circumstances in which it occurs. That is whether it develops in the 
community or in the hospital. It is also important to distinguish whether 
the kidney injury occurs as an isolated process, which is more common in 
community-acquired AKI, or if it occurs as part of multiorgan 
dysfunction syndrome. In the former, management is initially, 
conservative and follows an expectant approach. Renal replacement 
therapy is deferred when possible while awaiting the spontaneous 
recovery of renal function. In critically ill patients with multiorgan 
failure, dialysis should be started earlier. The goal is such cases is not 
simply control of azotemia but rather of renal support in an attempt to 
stabilize and optimize the physiologic parameters.
27 
More than 35 different definitions of AKI have been used in the 
recent literature.
28
 In 2007, the Acute Kidney Injury Network (AKIN), 
organized a summit of nephrology and critical care societies from around 
the world. The group endorsed the RIFLE criteria with a small 
modification to include small changes in serum creatinine  (> 0.3 mg/dl or 
> 26.5 mmol/l) when they occur within a 48-hour period.
24
 Two recent 
studies examining large databases in the USA
29
 and Europe
30
 validated 
these modified criteria. Thakar et al. found that increased severity of AKI 
was associated with an increased risk of death independent of 
comorbidity.
31 
 
 
 
DIAGNOSTIC CRITERIA FOR ACUTE KIDNEY INJURY
24 
An abrupt (within 48 hours) reduction in kidney function currently 
defined as an absolute increase in serum creatinine of more than or equal 
to 0.3 mg/dl (≥ 26.4 μmol/l), a percentage increase in serum creatinine of 
more than or equal to 50% (1.5-fold from baseline), or a reduction in 
urine output (documented oliguria of less than 0.5 ml/kg per hour for 
more than six hours). 
Classification/staging system for acute kidney injury
24 
Stage Serum creatinine criteria Urine output criteria 
1 Increase in serum creatinine of more 
than or equal to 0.3 mg/dl or increase 
to more than or equal to 150% to 200% 
(1.5- to 2-fold) from baseline 
Less than 0.5 ml/kg 
per hour for more than 
6 hours 
2 Increase in serum creatinine to more 
than 200% to 300% (> 2- to 3-fold) 
from baseline 
Less than 0.5 ml/kg 
per hour for more than 
12 hours 
3 Increase in serum creatinine to more 
than 300% (> 3-fold) from baseline (or 
serum creatinine of more than or equal 
to 4.0 mg/dl with an acute increase of 
at least 0.5 mg/dl, individuals who 
receive RRT) 
Less than 0.3 ml/kg 
per hour for 24 hours 
or anuria for 12 hours 
 
A big hurdle in the investigation and treatment of AKI is the timely 
identification of the syndrome. It is difficult to easily and reliably 
measure rapid changes in the GFR. Although the severity in reduction in 
GFR correlates with the onset of oliguria, the latter is insensate marker of 
the syndrome. This is because many patients with severe renal failure will 
remain non-oliguric. In AKI, there is poor agreement between serum 
creatinine and GFR. This is true at least until a serum creatinine has 
reached a steady state. Even then, the absolute increase in serum 
creatinine must take into reckoning variability in creatinine production 
rates.
42
  
As a result, definitions of AKI that are based on a fixed increment 
in serum creatinine would be expected to be biased toward making an 
early diagnosis in well-muscled as compared with malnourished subjects 
or in men as compared with women.  
INCIDENCE 
Acute kidney injury is a common and important diagnostic and 
therapeutic challenge for clinicians.
32
The incidence of AKI is difficult to 
estimate because no registry of its occurrence exists and because up until 
recently there was no standardized definition. From a variety of 
predominantly single centre studies it is estimated that 5% to 7% of 
hospitalized patients develop AKI.
33-36
 More detailed information is 
available regarding its development in the intensive care unit (ICU) 
environment, where approximately 25% to 30% of unselected patients 
develop some degree of AKI, although again estimates vary considerable 
depending on the definition used and the population case mix. Renal 
replacement therapy is typically required in 5% to 6% of the general ICU 
population or 8.8 to 13.4 cases per 100,000 population/year
37-42
 AKI is 
also a major medical complication in the developing world and in the 
tropics.
33
 In this setting, diarrheal illnesses, infectious diseases like 
malaria and leptospirosis, and natural disasters such as earthquakes are 
common.
33
 AKI is associated with a greatly increased risk of in-hospital 
mortality. In those admitted in the intensive care units, mortality rates 
may exceed 50%.
33
 
AKI IN THE DEVELOPING WORLD 
The epidemiology of AKI differs greatly between developed and 
developing countries. This is due to the differences in geography, 
demographics, economics, and co morbid diseases. While certain features 
of AKI are common to both, many aetiologies for AKI are region-specific 
such as infectious causes such as malaria and leptospirosis, 
envenomations from snakes, spider and caterpillar bites, and bee stings; 
and crush injuries from earthquakes and resultant 
rhabdomyolysis.
44
Factors responsible for this higher incidence of AKI in 
the tropics include hot climate in connection with excessive sweating, 
increased predisposition to hypovolemic insults, poor nutritional status 
and increased susceptibility to infections.  
ETIOLOGY 
The causes of AKI have traditionally been divided into three broad 
categories: prerenal azotemia, intrinsic renal parenchymal disease, and 
post renal obstruction.  
Prerenal AKI 
I.Hypovolemia 
A. Increased extracellular fluid losses: hemorrhage 
B. Gastrointestinal fluid loss: vomiting, diarrhea, enterocutaneous 
fistula  
C. Renal fluid loss: diuretics, osmotic diuresis, hypoadrenalism, 
nephrogenic diabetes insipidus. 
D. Extravascular sequestration: burns, pancreatitis, severe 
hypoalbuminemia  
E. Decreased intake: dehydration, altered mental status 
II. Altered renal hemodynamics resulting in hypoperfusion 
A. Low cardiac output state: disease of the myocardium, valves, and 
pericardium (including tamponade); pulmonary hypertension or 
massive pulmonary embolism leading to right and left heart failure; 
impaired venous return (e.g., abdominal compartment syndrome or 
positive pressure ventilation)  
B. Systemic vasodilatation: sepsis, antihypertensives, afterload 
reducers, anaphylaxis. 
C. Renal vasoconstriction: hypercalcemia, catecolamines, calcineurin 
inhibitors, amphotericin B. 
D. Impairment of renal autoregulatory responses: cyclooxygenase 
inhibitors (e.g., non-steroidal anti – inflammatory drugs), 
angiotensin – converting enzyme inhibitors, or angiotensin II 
receptor blockers. 
E. Hepatorenal syndrome 
 
Intrinsic AKI 
I. Renovascular obstruction (bilateral, or unilateral in the setting of one 
kidney) 
A. Renal artery obstruction: atherosclerotic plaque, thrombosis, 
embolism, dissection aneurysm, large vessel vasculitis 
B. Renal vein obstruction : thrombosis or compression 
II. Disease of the glomeruli or vasculature 
A. Glomerulonephritis or vasculitis 
B. Other : thrombotic microangiopathy, malignant hypertension, 
collagen vascular diseases (systemic lupus erythematosus, 
scleroderma), disseminated intravascular coagulation, preeclampsia 
 
III. Acute tubular necrosis 
A. Ischemia: causes are the same as for prerenal AKI, but generally 
the insult is more severe and / or more prolonged. 
B. Infection, with or without sepsis syndrome 
C. Toxins: 
1. Exogenous: radiocontrast, calcineurin inhibitors, antibiotics (e.g., 
aminoglycosides), chemotherapy (e.g., cisplatin), antifungals (e.g., 
amphotericin B), ethylene glycol, snake bites.   
2. Endogenous : rhabdomyolysis, haemolysis 
IV. Interstitial nephritis 
A. Allergic: antibiotics (β – lactams, sulfonamides, quinolones, 
rifampicin), nonsteroidal anti – inflammatory drugs, diuretics, 
other drugs. 
B. Infection: pyelonephritis (if  bilateral) 
C. Infiltration: lymphoma, leukemia, sarcoidosis 
D. Inflammatory, nonvascular : Sjogeren’s syndrome, 
tubulointerstitial nephritis with uveitis 
V. Intratubular obstruction 
A. Endogenous : myeloma proteins, uric acid, tumor lysis syndrome 
B. Exogenous: acyclovir, gancyclovir, methotrexate, indinavir 
Postrenal AKI (Obstruction) 
I.Ureteric (bilateral, or unilateral in the case of one kidney): calculi, blood 
clots, sloughed papillae, cancer, external compression (e.g., 
retroperitoneal fibrosis) 
II. Bladder neck: neurogenic bladder, prostatic hypertrophy, calculi, 
blood clots, cancer. 
III. Urethra : stricture or congenital valves 
 
 
 
PRERENAL AZOTEMIA (PRERENAL AKI) 
Prerenal AKI is the most common cause of AKI and is an 
appropriate physiologic response to renal hypoperfusion.
2,12,43 
By 
definition, the integrity of renal parenchymal tissue is maintained and 
GFR is corrected rapidly with restoration of renal perfusion. Severe renal 
hypoperfusion may cause ischemic AKI. Thus, prerenal AKI and 
ischemic AKI are manifestations of the same spectrum of renal 
hypoperfusion. The clinical and biochemical features of prerenal AKI and 
ischemic AKI may coexist in many patients. 
Prerenal AKI can complicate any disease characterized by 
hypovolemia, low cardiac output, systemic vasodilatation, or intrarenal 
vasoconstriction. Hypovolemia leads to a fall in mean systemic arterial 
pressure. This in turn, activates carotid sinus and cardiac baroreceptors. 
This initiates a series of neural and humoral responses. This includes 
activation of the sympathetic nervous system, renin-angiotensin-
aldosterone system and release of antidiuretic hormone.
44-46 
Nor 
epinephrine, angiotensin II, and antidiuretic hormone act in synchrony. 
They do so to maintain BP, cardiac and cerebral perfusion. They inhibit 
salt loss through sweat glands, by stimulating vasoconstriction in 
musculocutaneous and splanchnic circulations, by stimulating thirst and 
salt appetite, and by promoting renal salt and water retention. Glomerular 
perfusion, filtration rate and ultra filtration pressure are preserved during 
mild hypoperfusion through compensatory mechanisms. Stretch receptors 
present in the walls of afferent arterioles detect a reduction in perfusion 
pressure. This triggers relaxation of the afferent arteriolar smooth muscle 
cells and vasodilatation. Intrarenal biosynthesis of vasodilator 
prostaglandins (e.g., prostacyclin, prostaglandin E2), kallikrein and 
kinins, and possibly nitric oxide (NO) is enhanced. Angiotensin II may 
induce preferential constriction of efferent arterioles, probably because 
most angiotensin II receptors are found at this location.
47
 As a result, 
intraglomerular pressure is preserved, the fraction of renal plasma that is 
filtered by glomeruli (filtration fraction) is increased, and GFR is 
maintained. These compensatory renal responses are overwhelmed during 
states of moderate to severe hypoperfusion, and AKI ensues. Auto 
regulatory dilatation of afferent arterioles is maximal at a mean systemic 
arterial blood pressure of about 70 to 80 mm Hg, and hypotension below 
this level is associated with a precipitous decline in glomerular 
ultrafiltration pressure and GFR.
48,49
 
 
Several classes of commonly used drugs impair renal adaptive 
responses and can convert compensated renal hypoperfusion to overt 
prerenal AKI or trigger progression of prerenal AKI to ischemic AKI.
50
 
Non-steroidal anti-inflammatory drugs (NSAIDs), including 
cyclooxygenase II (COX-II) inhibitors, inhibit renal prostaglandin 
biosynthesis. They do not compromise GFR in normal individuals but 
may precipitate prerenal AKI in subjects with true hypovolemia or 
decreased effective arterial blood volume, or in patients with CKD in 
whom GFR is maintained in part by prostaglandin-mediated 
hyperfiltration through remnant nephrons.
51-54
 Similarly, inhibitors of 
angiotensin-converting enzyme (ACE) and angiotensin II receptor 
blockers (ARBs) may trigger prerenal AKI in individuals in whom 
intraglomerular pressure and GFR are dependent on angiotensin II. This 
is seen in bilateral renal artery stenosis or unilateral stenosis in a solitary 
functioning kidney.
55
 Here, angiotensin II preserves glomerular filtration 
pressure distal to renal arterial stenosis by increasing systemic arterial 
pressure and by triggering selective constriction of efferent arterioles. 
ACE inhibitors and ARBs blunt these compensatory responses and 
precipitate reversible AKI in such patients. ACE inhibitors or ARBs, like 
NSAIDs, may also precipitate prerenal AKI in patients with compensated 
renal hypoperfusion of other causes. This mandating close monitoring of 
the serum creatinine level when these drugs are given to patients with 
high-risk factors. 
INTRINSIC AKI 
The most common causes of intrinsic AKI are sepsis, ischemia, 
and nephrotoxins, both endogenous and exogenous. Ischemic ATN and 
toxic ATN account for about 80% to 90% of intrinsic AKI.
56,57
 From a 
clinicopathologic viewpoint, it is helpful to categorize the causes of 
intrinsic AKI into the following categories:
26 
  •     Diseases involving large renal vessels, 
   •     Diseases of the renal microvasculature and glomeruli, 
   •     Ischemic and nephrotoxic ATN, and 
   
•     Other acute processes involving the tubulointerstitium. 
 
 
DISEASES OF LARGE RENAL VESSELS, 
MICROVASCULATURE AND TUBULOINTERSTITIUM 
Occlusion of large renal vessels is an uncommon cause of AKI. To 
affect BUN and serum creatinine, occlusion must be either bilateral or 
unilateral in patients with underlying chronic renal insufficiency or a 
solitary functioning kidney. Atheroemboli are the most common culprits 
and are usually dislodged from an atheromatous aorta during 
arteriography, angioplasty, or aortic surgery. Cholesterol emboli lodge in 
medium or small renal arteries. Renal artery thrombosis is usually 
superimposed on an atheromatous plaque but may also complicate 
traumatic intimal tears or the site of surgical anastomosis after renal 
transplantation. Outside of the immediate post-transplantation period, 
renal vein thrombosis is an exceedingly rare cause of AKI and is usually 
encountered as a complication of the nephrotic syndrome in adults or of 
severe dehydration in children.
 
Virtually all diseases that compromise blood flow within the renal 
microvasculature may induce AKI.
 
These include inflammatory (e.g., 
glomerulonephritis or vasculitis) and noninflammatory (e.g., malignant 
hypertension) diseases of the vessel wall, thrombotic microangiopathies, 
and hyperviscosity syndromes. 
SEPSIS-ASSOCIATED AKI 
     Sepsis is an important cause of AKI in the developing world. It 
markedly accentuates the risk of mortality. Most cases of severe AKI 
typically occur in the setting of hemodynamic collapse. Sepsis induces 
renal hypoperfusion by provoking a combination of systemic 
vasodilatation and intrarenal vasoconstriction.
58-63
There is clear evidence 
of tubular injury in sepsis associated AKI. Post-mortem examinations of 
kidneys from individuals with severe sepsis also suggest that other factors 
are involved. These factors which are related to inflammation and 
interstitial edema, must also be considered in the pathophysiology of 
sepsis-induced AKI. 
ISCHEMIA-ASSOCIATED AKI 
Even though healthy kidneys constitute only 0.5% of the human 
body, they receive 20% of the cardiac output and account for 10% of 
resting oxygen consumption. The renal medulla is also the site of one of 
the most hypoxic regions in the body. It is particularly vulnerable to 
ischemic damage. This is because of the architecture of the blood vessels 
that supply oxygen and nutrients to the tubules. Ischemia alone in a 
normal kidney is usually not sufficient to cause severe AKI. This fact is 
evidenced by the relatively low risk of severe AKI even after total 
interruption of renal blood flow during suprarenal aortic clamping or 
cardiac arrest. Clinically, AKI more commonly develops when ischemia 
occurs in the context of limited renal reserve. This can happen in chronic 
kidney disease or older age. It can also occur with coexisting insults such 
as sepsis, vasoactive or nephrotoxic drugs, rhabdomyolysis, and 
inflammatory states associated with burns and pancreatitis. Prerenal 
azotemia and ischemia-associated AKI represent a continuum of the 
manifestations of renal hypoperfusion. Prerenal AKI differs from 
ischemic AKI. Ischemic AKI is associated with injury to renal 
parenchyma. This injury does not resolve immediately on restoration of 
perfusion. In its more extreme form, it may result in bilateral acute renal 
cortical necrosis and irreversible renal failure. Persistent preglomerular 
vasoconstriction is also an underlying cause of the reduction in GFR seen 
in AKI. Factors implicated for vasoconstriction are activation of 
tubuloglomerular feedback from enhanced delivery of solute to the 
macula densa following proximal tubule injury, increased basal vascular 
tone and reactivity to vasoconstrictive agents, and decreased vasodilator 
responsiveness. Back leak of filtrate across ischemic and denuded tubular 
epithelium and mechanical obstruction of tubules from necrotic debris 
also contributes to low GFR. 
AKI IN DIARRHEAL DISEASE 
Two major causes responsible for the wide prevalence of AKI in 
tropics are poor socioeconomic conditions and lack of clean water supply. 
Diarrheal diseases account for 5-10 million deaths/year. Diarrheal 
diseases are responsible for most cases of AKI in children in India. The 
incidence of ADD increases with the starting of summer. The maximum 
number of cases occurs during the rainy season. Early use of oral 
rehydration therapy and an improvement in the standards of living in a 
decline of AKI related to diarrheal diseases. 
Renal failure occurring in diarrheal disease is usually oliguric. 
Patients have metabolic acidosis out of proportion to the degree of renal 
failure. This is due to loss of bicarbonate in the diarrheal fluid. due to the 
loss of large amounts of potassium in the diarrheal stools, hypokalemia 
may occur. This can in turn cause paralytic ileus. Acute tubular necrosis 
is the most common histological lesion seen in renal failure associated 
with diarrheal disease. Acute cortical necrosis can also occur. 
NEPHROTOXIN-ASSOCIATED AKI 
The kidney has very high susceptibility to nephrotoxicity due to 
extremely high blood perfusion and concentration of circulating 
substances along the nephron where water is reabsorbed and in the 
medullary interstitium; this results in high-concentration exposure of 
toxins to tubular, interstitial, and endothelial cells. All structures of the 
kidney are vulnerable to toxic injury, including the tubules, interstitium, 
vasculature, and collecting system. As with other forms of AKI, risk 
factors for nephrotoxicity include older age, chronic kidney disease 
(CKD), and prerenal azotemia. Hypoalbuminemia may increase the risk 
of some forms of nephrotoxin-associated AKI due to increased free 
circulating drug concentrations. Nephrotoxic ATN complicates the use of 
many structurally different drugs and poisons.
64-68
 In general, 
nephrotoxins cause renal injury by inducing a varying combination of 
intrarenal vasoconstriction, direct tubule toxicity, and intratubular 
obstruction.. The nephrotoxic potential of most agents is dramatically 
increased in the presence of borderline or overt renal ischemia, sepsis, or 
other renal insults. 
CONTRAST AGENTS 
Iodinated contrast agents used for cardiovascular and CT imaging 
are a leading cause of AKI. Acute intra-renal vasoconstriction is an 
important pathophysiologic event in AKI associated with radiocontrast 
agents (contrast nephropathy). Contrast nephropathy typically presents as 
an acute decline in GFR within 24 to 48 hours of administration, a peak 
in serum creatinine value after 3 to 5 days, and return of the serum 
creatinine value to the ―normal‖ range within 1 week.106,107 Individuals 
with chronic renal insufficiency (serum creatinine >2.0 mg/dL) are at the 
greatest risk of contrast-induced renal injury.
69
 Other risk factors include 
diabetic nephropathy, congestive heart failure, jaundice, volume 
depletion, multiple myeloma, the volume of contrast used, and the 
coincident use of ACE inhibitors or NSAIDs. Patients usually present 
with benign urine sediment, concentrated urine, and low fractional 
excretion of Na
+
 and, thus, have many features of prerenal AKI; however, 
in more severe cases, tubule cell injury may be evident. 
ANTIBIOTICS 
Therapeutic agents that are directly toxic to renal tubule epithelium 
include antimicrobials such as aminoglycosides, amphotericin B, 
acyclovir, indinavir, cidofovir, pentamidine, and foscarnet.
70-73 
  Nonoliguric AKI (i.e., without a significant reduction in urine 
volume) accompanies 10–30% of courses of aminoglycoside antibiotics, 
even when plasma levels are in the therapeutic range. Aminoglycosides 
are polycations and are freely filtered across the glomerular filtration 
barrier and accumulated by proximal tubule cells by absorptive 
endocytosis after interaction with negatively charged phospholipid 
residues on brush border membranes. Important risk factors for 
aminoglycoside nephrotoxicity include use of high or repeated doses or 
prolonged therapy, pre-existing renal insufficiency, advanced age, 
volume depletion, and the coexistence of renal ischemia or other 
nephrotoxins.
74
 Although the precise sub cellular mechanisms by which 
aminoglycosides perturb renal function has not yet been fully elucidated, 
gentamicin has been demonstrated to bind to megalin, an endocytic 
receptor in the clathrin-coated pits of the apical cell membrane. When 
endocytosed, this complex may induce cellular injury by inhibiting 
endosomal fusion events. AKI typically manifests after 5–7 days of 
therapy and can present even after the drug has been discontinued. 
Hypomagnesaemia is a common finding and suggests coexistent injury to 
the thick ascending limb of the loop of Henle, the major site of Mg
2+
 
reabsorption. 
Nephrotoxicity from amphotericin B is dose and duration 
dependent. AKI is almost invariable in patients receiving cumulative 
doses of amphotericin B of more than 1 g and is a common complication 
even with lower doses.
75 
This drug binds to tubular membrane cholesterol 
and introduces pores. Amphotericin B induces direct renal 
vasoconstriction and exerts direct toxicity on a variety of tubular 
segments. The tubular dysfunction is manifested by an increase in 
tubuloglomerular feedback with resultant suppression of GFR, ATN, 
hypomagnesaemia, hypophosphatemia, hypocalcaemia, and a renal 
tubular acidosis due to back leakage of secreted H
+
 in the distal cortical 
nephron. ATN due to amphotericin B is typically reversible, but chronic 
use can lead to nephrocalcinosis. Clinical features of amphotericin B 
nephrotoxicity include polyuria, hypomagnesaemia, hypocalcaemia, and 
non-gap metabolic acidosis. 
High-dose intravenous acyclovir causes AKI within 24 to 48 hours 
in 10% to 30% of patients, particularly if they are volume depleted or if 
the drug is administered as a bolus.
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 AKI is usually nonoliguric; 
frequently associated with colic, nausea, and vomiting; and appears to be 
induced by intratubular precipitation of acyclovir crystals. A similar 
syndrome in now recognized in patients receiving the oral antiretroviral 
drug indinavir.
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 Asymptomatic crystaluria in seen in up to 10% of 
patients, with half this number presenting with loin pain and hematuria. 
A Fanconi-like syndrome is seen in up to 40% of patients receiving 
adefovir, a nucleoside reverse transcriptase inhibitor due to a direct toxic 
effect on tubular cell mitochondrial function. A similar syndrome has also 
been described with tenofovir. Cidofovir, a nucleotide analog used to 
treat cytomegalovirus infections is also nephrotoxic. Pentamidine induces 
AKI in 25% to 95% of patients, usually during the second week of 
therapy and frequently in association with hypomagnesaemia, hypo- or 
hyperkalemia, and a distal renal tubular acidosis. 
The mechanism of injury is unclear but may involve an immune 
process, because AKI does not appear to be dose dependent and is often 
associated with pyuria, hematuria, proteinuria, and casts. Foscarnet 
causes a distinct pattern of renal injury characterized by nonoliguric, 
often polyuric, AKI within 7 days, hyperphosphatemia, ATN, interstitial 
fibrosis, and a slow recovery that may take months. ATN complicates up 
to 70% of courses of cisplatin and ifosfamide, two commonly used 
chemotherapeutic agents. 
Vancomycin may be associated with AKI, particularly when trough 
levels are high, but a causal relationship with AKI has not been 
definitively established. 
Foscarnet, pentamidine, and cidofovir (less commonly prescribed 
antimicrobials) are also frequently associated with AKI due to tubular 
toxicity. 
TOXIC INGESTIONS 
Poisoning with Super Vasmol; a commonly used hair dye, in South 
India have been reported.
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 This dye is composed of 
paraphenylenediamine (PPD), ethylene diamine tetra acetic acid (EDTA), 
propylene glycol, liquid paraffin, cetostearyl alcohol, sodium 
laurylsulphate and resorcinol. Resorcinol, being a phenol, has been 
postulated to cause renal failure, while EDTA which may be present may 
cause hypocalcaemia. The most common cause of death in these patients 
is acute renal failure, which occurs as a result of the nephrotoxic 
components of this hair dye, as well as due to rhabdomyolysis. 
Myoglobin, which was released as a result of rhabdomyolysis, has been 
implicated in heme induced renal damage, mainly by causing oxidative 
damage to the renal tubules. However, renal failure can also occur as a 
result of other nephrotoxic chemicals which are present in the Super 
Vasmol dye. Apart from PPD, propylene glycol and resorcinol which are 
present in the Super Vasmol dye can result in acute tubular necrosis. 
The extensive use of copper sulphate in leather industry, its low 
cost and easy availability are the main reasons for its use as a mode of 
suicide among the poor socioeconomic groups in India. AKI develops in 
20-40% of patients with acute copper sulphate poisoning and is invariably 
oliguric.
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 The possible mechanisms of kidney damage include; pre-
renal failure due to dehydration (vomiting, diarrhoea, reduced fluid 
intake), haemoglobinuria, sepsis, rhabdomyolysis, direct copper toxicity 
on proximal tubules and secondary effects of multi organ dysfunction. 
The recovery of renal function following copper sulphate ingestion is 
observed to be slow and incomplete. 
Ethylene glycol, present in automobile antifreeze, is metabolized to 
oxalic acid, glycolaldehyde, and glyoxylate, which may cause AKI 
through direct tubular injury. Diethylene glycol is an industrial agent that 
has been the cause of outbreaks of severe AKI around the world due to 
adulteration of pharmaceutical preparations. The metabolite 2-
hydroxyethoxyacetic acid (HEAA) is thought to be responsible for 
tubular injury. Melamine contamination of foodstuffs has led to 
nephrolithiasis and AKI, either through intratubular obstruction or 
possibly direct tubular toxicity. Aristolochic acid was found to be the 
cause of "Chinese herb nephropathy" and "Balkan nephropathy" due to 
contamination of medicinal herbs or farming. The list of environmental 
toxins is likely to grow and contribute to a better understanding of 
previously catalogued "idiopathic" chronic tubular interstitial disease, a 
common diagnosis in both the developed and developing world. 
SNAKE BITES AND AKI 
Although nearly all snakes with medical relevance can induce AKI, 
it is unusual except with bites by Russell’s viper, E.Carinatus, and 
members of the genera Crotalus and Bothrops. The most prevalent areas 
for these snakes are Asia and South America. In India AKI is mostly 
associated with Russell’s viper and E.carinatus bites. In India, the 
incidence of AKI following snake bite is 13-32%
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The AKI following snake bite may be due to a number of factors 
like bleeding, hypotension, circulatory collapse, intravascular hemolysis, 
DIC, microangiopathic haemolytic anemia and direct nephrotoxicity of 
the venom. Renal histology shows predominantly either acute tubular or 
cortical necrosis. Early administration of ASV is vital in patients with 
evidence of systemic envenomation as it may prevent hematologic 
abnormalities and renal complications. 
ENDOGENOUS TOXINS 
Myoglobin, hemoglobin, uric acid, and myeloma light chains are 
the endogenous toxins that are most commonly associated with AKI.  
PIGMENT INDUCED AKI 
Renal dysfunction complicates approximately 30% of cases of 
rhabdomyolysis.
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 Rhabdomyolysis may result from traumatic crush 
injuries, muscle ischemia during vascular or orthopaedic surgery, 
compression during coma or immobilization, prolonged seizure activity, 
excessive exercise, heat stroke or malignant hyperthermia, infections, 
metabolic disorders (e.g., hypophosphatemia, severe hypothyroidism), 
and myopathies (drug-induced, metabolic, or inflammatory). In the 
tropics, common causes of non traumatic rhabdomyolysis producing 
myoglobinuric AKI are eclampsia, prolonged labour, poisoning with 
mercuric chloride or zinc phosphide, status epilepticus, viral myositis, 
burns and electrical injury.
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Hemoglobin-induced ATN is rare and is most commonly 
encountered after blood transfusion reactions.
89
 Acute hemolysis in G6PD 
deficient individuals is a frequent cause of AKI in some populations of 
our country, producing AKI in 5- 10% of cases.
6
 Pathogenic factors for 
AKI include intrarenal vasoconstriction, direct proximal tubular toxicity, 
and mechanical obstruction of the distal nephron lumen when myoglobin 
or hemoglobin precipitates with Tamm-Horsfall protein (uromodulin, the 
most common protein in urine and produced in the thick ascending limb 
of the loop of Henle), a process favoured by acidic urine.
90-93
  
Acute uric acid nephropathy typically complicates treatment of 
lymphoproliferative or myeloproliferative disorders and is usually 
associated with other biochemical evidence of tumor lysis such as 
hyperkalemia, hyperphosphatemia, and hypocalcemia.
94
 Acute uric acid 
nephropathy is rare when plasma concentrations are less than 15 to 20 
mg/dL but may be precipitated at relatively low levels by volume 
depletion or low urine pH. Casts, composed of filtered immunoglobulin 
light chains and other urinary proteins such as Tamm-Horsfall protein 
(THP), induce AKI in patients with multiple myeloma (myeloma-cast 
nephropathy).
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AKI IN LEPTOSPIROSIS 
In tropical countries, where the disease is endemic, leptospirosis is 
an important cause of AKI. The incidence of AKI varies from 10% to 
60%, depending on the severity of the disease, age, and definition of 
AKI.
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Renal involvement in leptospirosis can vary from a subclinical 
course, with mild proteinuria and urinary sediment abnormalities, to 
severe AKI. Acute kidney injury usually presents with a rapid elevation 
in serum urea and creatinine, and can be associated with jaundice. Kidney 
injury in patients with hyperbilirubinemia represents a severe form, 
frequently accompanied by oliguria-anuria.
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 Acute kidney injury due to 
leptospirosis usually presents in the non-oliguric form with hypokalemia, 
which can be detected in 41% to 45% of the patients with leptospirosis 
associated with AKI. Tubular dysfunctions, mainly of the proximal 
tubule, are very common, even in the absence of AKI. Alterations, such 
as bicarbonaturia, glycosuria, and a reduction in sodium proximal 
reabsorption and uric acid and phosphate excretion, have been observed, 
and a deficit in the urinary concentration can persist for prolonged 
periods.
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 Hypokalemia is a frequent finding in AKI of leptospirosis, and 
can be observed in 45% to 74% of patients on hospital admission, 
requiring intravenous potassium replacement in 80% of the cases. In the 
AKI of leptospirosis, even oliguric patients do not usually have 
hyperkalemia. Hypokalemia is the most characteristic laboratory finding 
of AKI of leptospirosis. Thus, AKI of leptospirosis, regardless of its 
severity, hypercatabolism, rhabdomyolysis, acidosis, and oliguria, is 
characterized by normo- or hypokalemia. That is a relevant characteristic 
of AKI due to leptospirosis at the time of diagnosis. Another early 
characteristic of kidney injury is the ultrasound finding of enlarged 
kidneys, with relatively normal parenchymal echogenicity, indicating 
tubulointerstitial nephritis.
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 The major factors involved in the 
pathogenesis of AKI in leptospirosis are the direct nephrotoxic action of 
the leptospira and the toxin-induced immune response. Hemodynamic 
alteration, jaundice, and rhabdomyolysis are also associated with the 
genesis of AKI in leptospirosis. AIN is the major causing mechanism of 
AKI.
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PATHOPHYSIOLOGY OF KIDNEY DYSFUNCTION IN 
ACUTE KIDNEY INJURY 
The effect of renal injury, whether from ischemia or from other 
causes, is a profound decrease in the GFR. This large decrease in 
filtration capacity of the kidney often occurs in the absence 
overwhelmingly evident damage to the kidney as seen on light 
microscopy. There are at least three major classic proposed mechanisms 
for the fall in GFR, as determined by micropuncture studies on animals 
and indirect methods in humans. The first mechanism is a drop in the 
filtration pressure in the glomerulus. This drop in pressure is caused by 
afferent arteriolar vasoconstriction and proximal tubular obstruction.
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This first mechanism leads to a direct fall in the GFR. Afferent arteriolar 
vasoconstriction is thought to be a result of endothelial cell injury.
102 
This 
leads to an imbalance in vasoactive substances, with a predominance of 
vasoconstrictive activity. The second mechanism, tubular back-leakage, 
leads to a fall in the effective GFR. Back-leakage of glomerular filtrate 
occurs in the setting of damage and loss of epithelial cells and loss of 
tight junctions between those cells that are critical to maintaining 
separation of tubular filtrate and the surrounding interstitium.
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Tight 
junctions are disrupted in the setting of adenosine triphosphate (ATP) 
depletion, allowing back-leakage of sodium and other solutes into the 
renal interstitium.
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The third mechanism, tubular obstruction, is a result 
of cast formation from sloughed tubular epithelial cells as well as THP. 
THP tends to polymerize and form a gel that can further trap cells and 
tubular cell debris following AKI. The concentration of various 
molecules in the renal tubules in evolving ATN further promotes THP gel 
formation. Besides a fall in GFR, there is also a decreased ability of the 
kidney to concentrate urine following AKI. This is due in part to the loss 
of aquaporin water channel expression in different parts of the nephron 
including the collecting duct and the proximal tubules. Sodium and acid-
base transporters are also dysregulated by kidney injury.
 
DISTANT ORGAN PATHOPHYSIOLOGY 
AKI is a systemic disease, and with the availability of dialysis, 
most deaths during AKI are due to hypotension, cardiorespiratory failure, 
sepsis, and gastrointestinal bleeding. Organ cross-talk during AKI is 
being increasingly studied, and may help explain the excess morbidity 
and mortality associated with even mild degrees of acute kidney 
impairment. There is a strong association between AKI and acute lung 
injury, and the mortality rate during AKI rises from 50% to 80% when 
both lung and kidney are involved. Evidence for direct AKI-induced 
distant organ dysfunction was demonstrated when clamping of the renal 
artery in rats increased pulmonary vascular permeability with 
microvascular inflammation and both leukocyte and RBC sludging. 
Acute ischemic kidney injury can also produce cross-talk between the 
kidney and bone marrow, perhaps supporting or enhancing the 
inflammation that is seen during AKI. Cross-talk between the kidney and 
liver has also been demonstrated in the setting of AKI. The injured 
kidney produces IL-6, which exerts local proinflammatory and distant 
anti-inflammatory effects. 
COURSE OF ACUTE TUBULE NECROSIS 
The clinical course of ATN can be divided into three phases: the 
initiation, maintenance phase, and recovery phases. The initiation phase is 
the period when patients are exposed to the ischemia or toxins and 
parenchymal renal injury is evolving but not yet established. ATN is 
potentially preventable during this period, which may last hours to days. 
The initiation phase is followed by a maintenance phase, during which 
parenchymal injury is established and GFR stabilizes at a value of 5 to 10 
mL/min.
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 Urine output is usually lowest during this period. The 
maintenance phase typically lasts 1 to 2 weeks but may be prolonged for 
1 to 11 months before recovery. The recovery phase is the period, during 
which patients recover renal function through repair and regeneration of 
renal tissue. Its onset is typically heralded by a gradual increase in urine 
output and a fall in serum creatinine, although the latter may lag behind 
the onset of diuresis by several days. This post-ATN diuresis may reflect 
appropriate excretion of salt and water accumulated during the 
maintenance phase, osmotic diuresis induced by filtered urea and other 
retained solutes, and the actions of diuretics administered to hasten salt 
and water excretion.
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 Occasionally, diuresis may be inappropriate 
and excessive if recovery of tubule reabsorptive processes lags behind 
glomerular filtration, although this phenomenon is more common after 
relief of urinary tract obstruction.
 
 
DIAGNOSTIC EVALUATION 
A graph of remote and recent serum creatinine levels versus time, 
incorporating drug therapy and interventions, is invaluable for 
differentiation of acute and chronic renal failure and the identification of 
the cause of AKI. When previous measurements are not available, 
anemia, hyperparathyroidism, neuropathy, band keratopathy, and 
radiologic evidence of renal osteodystrophy or small scarred kidneys are 
useful indicators of a chronic process. However, it should be noted that 
anemia may also complicate AKI, particularly if  prolonged, and renal 
size can be normal or increased in a variety of chronic renal diseases 
(e.g., diabetic nephropathy, amyloid, polycystic kidney disease). Once a 
diagnosis of AKI is established, attention should focus on the 
differentiation between prerenal, intrinsic renal, and postrenal AKI, and 
the identification of the specific causative disease. 
Clinical Approach to the Diagnosis of Acute Kidney Injury 
History, physical examination (including fundoscopy and weight), 
detailed view of hospital chart, previous records, and drug history 
Urinalysis including specific gravity, dipstick, sulfosalicylis acid, 
microscopy, and staining for eosinophils 
Flow chart of serial blood pressure, weight, BUN, serum creatinine, 
major clinical events, interventions, and therapies 
Routine blood chemistry assays (BUN, creatinine, Na
+
,K
+
,Ca2
+
,HCO3
-
, 
Cl
-
, PO4
3-
 and hematologic tests. 
 Selected special investigation: 
       Urine chemistry, eosinophils, and/or immunoelectrophoresis 
      Serologic tests: antiglomerular basement membrane antibodies,  
      antineutrophil cytoplasmic antibodies, complement, antinuclear   
      antibodies, serum protein electrophoresis, anti – streptolysin O or anti    
      – DNAase titers 
      Radiologic evaluation : plain abdominal film, renal ultrasonography,  
      intravenous pyelography, renal angiography, magnetic resonance  
      angiography. 
Renal biopsy 
 
CLINICAL ASSESSMENT 
Prerenal AKI should be suspected when the serum creatinine value 
rises after hemorrhage. Supportive findings on clinical assessment 
include symptoms of thirst or orthostatic dizziness and objective evidence 
of orthostatic hypotension (postural fall in diastolic pressure greater than 
10 mm Hg) and tachycardia (postural increase of more than 10 
beats/min). However, florid symptoms or signs of hypovolemia are 
usually not manifest until extracellular fluid volume has fallen by 10% to 
20%. Nursing and pharmacy records should be reviewed for recent use of 
analgesics and anti-hypertensives. Consideration should be given to the 
misuse of illicit drugs such as cocaine. Clinical examination may show 
signs of chronic liver disease (e.g., palmar erythema, jaundice, 
telangiectasia, caput medusae, splenomegaly, ascites), advanced cardiac 
failure (e.g., peripheral edema, hepatic congestion, ascites, elevated 
jugular venous pressure, bibasilar lung crackles, pleural effusion, 
cardiomegaly, gallop rhythm, cold extremities), or other causes of 
reduced effective critical blood volume.  
Definitive diagnosis of prerenal AKI hinges on prompt resolution 
of AKI after restoration of renal perfusion. There is a high likelihood of 
ischemic ATN if AKI follows a period of severe renal hypoperfusion and 
persists despite restoration of renal perfusion.
 
It should be noted, 
however, that significant hypotension is recorded in the case notes of less 
than 50% of patients with postsurgical ATN. The diagnosis of 
nephrotoxic ATN requires scouring of clinical, pharmacy, nursing, and 
radiology records for evidence of recent administration of nephrotoxic 
medications or radiocontrast agents.
 
AKI after cancer chemotherapy 
suggests a diagnosis of tumor lysis syndrome and acute urate 
nephropathy, although other diagnoses must be considered.
 
Pigment-
induced ATN may be suspected if the clinical assessment reveals clues to 
rhabdomyolysis (e.g., seizures, excessive exercise, alcohol or drug abuse, 
muscle tenderness, limb ischemia) or hemolysis (e.g., recent transfusion).
 
Although most AKI is either prerenal or due to ischemic and 
nephrotoxic ATN, patients should be assessed carefully for evidence of 
other renal parenchymal diseases, because many of the latter are treatable 
and their diagnosis alters management and prognosis.  
Increased urinary protein excretion, characteristically less than 1 g/d, is a 
common finding in ischemic or nephrotoxic AKI and reflects both failure 
of injured proximal tubule cells to reabsorb normally filtered protein and 
excretion of cellular debris (tubule proteinuria). Heavy proteinuria is also 
a frequent finding (80%) in patients with allergic interstitial nephritis 
triggered by NSAIDs. These patients have a glomerular lesion that is 
almost identical to minimal-change glomerulonephritis, in addition to 
acute interstitial inflammation.
 
A similar syndrome has been reported in 
patients receiving other agents such as ampicillin, rifampicin, and 
interferon alfa.
 
Hemoglobinuria or myoglobinuria should be suspected if 
urine is strongly positive for hemoglobin by dipstick but contains few 
RBCs and if the supernatant of centrifuged urine is pink and also positive 
for free hemoglobin. Hemolysis and rhabdomyolysis can usually be 
differentiated by inspection of plasma. The latter is usually pink in 
hemolysis, but not in rhabdomyolysis, because free hemoglobin (65,000 
daltons) is a larger molecule than myoglobin (17,000 daltons) that is 
heavily protein bound and filtered slowly by the kidney. 
CONFIRMATORY TESTS 
The pattern of change in serum creatinine value often provides 
clues to the cause of AKI. Prerenal AKI is typified by rapid fluctuations 
in creatinine that parallel changes in hemodynamic function and renal 
perfusion.  
Imaging of the urinary tract by plain film of the abdomen, 
ultrasonography, computed tomography (CT), or magnetic resonance is 
recommended for most patients with AKI to distinguish between acute 
and chronic renal failure and exclude acute obstructive uropathy.
 
The 
plain film of the abdomen, with tomography if necessary, usually 
provides a reliable index of kidney size and may detect Ca
2+
-containing 
kidney stones. However, the capacity of ultrasonography to determine 
cortical thickness, differences in cortical and medullary density, and the 
integrity of the collecting system, in addition to kidney size, makes it the 
screening modality of choice in most cases of AKI.
 
Although 
pelvicalyceal dilatation is usual in cases of urinary tract obstruction (98% 
sensitivity), dilatation may not be observed in the volume-depleted 
patient during the initial 1 to 3 days after obstruction when the collecting 
system is relatively noncompliant or in patients with obstruction caused 
by ureteric encasement or infiltration (e.g., retroperitoneal fibrosis, 
neoplasia). CT scanning has largely replaced retrograde pyelography 
through cystography or percutaneous anterograde pyelography for 
definitive diagnosis when obstruction without dilatation is considered 
likely. The latter procedures remain useful for precise localization of the 
site of obstruction in selected cases and facilitate decompression of the 
urinary tract. Intravenous pyelography should be avoided in patients with 
AKI to avoid adding contrast nephropathy to already compromised renal 
function. Radionuclide scans have been touted as useful for assessing 
renal blood flow, glomerular filtration, tubule function, and infiltration by 
inflammatory cells in AKI; however, these tests generally lack specificity 
or yield conflicting or poor results in controlled studies and their use is 
largely restricted to the immediate postrenal transplantation period. 
Magnetic resonance angiography (MRA) of the kidneys is extremely 
useful for detecting renal artery stenosis, and its role has been extended to 
the evaluation of acute renovascular crises.
 
MRA is a time-efficient and 
safe test when compared with conventional arteriography. Doppler 
ultrasonography and spiral CT are also useful in patients with suspected 
vascular obstruction; however, contrast angiography remains the gold 
standard for definitive diagnosis. 
Renal biopsy is usually reserved for patients in whom cause of 
intrinsic AKI is not clear. Prerenal and postrenal failure should be 
excluded. Examples include antiglomerular basement membrane disease 
and other forms of necrotizing glomerulonephritis, vasculitis, HUS and 
TTP, allergic interstitial nephritis, myeloma cast nephropathy, and acute 
allograft rejection. 
NOVEL BIOMARKERS 
BUN and creatinine are functional biomarkers of glomerular 
filtration rather than tissue injury biomarkers and, therefore, may be 
suboptimal for the diagnosis of actual parenchymal kidney damage. BUN 
and creatinine are also relatively slow to rise after kidney injury. Several 
novel kidney injury biomarkers have been investigated and show great 
promise for the early and accurate diagnosis of AKI. New biomarkers 
hold the promise of allowing clinicians to detect kidney injury earlier, to 
guide future therapy, and to better prognosticate.  
Kidney injury molecule-1 (KIM-1) is a type 1 transmembrane 
protein that is abundantly expressed in proximal tubular cells injured by 
ischemia or nephrotoxins such as cisplatin. KIM-1 is not expressed in 
appreciable quantities in the absence of tubular injury or in extrarenal 
tissues. KIM-1's functional role may be to confer phagocytic properties to 
tubular cells, enabling them to clear debris from the tubular lumen after 
kidney injury. KIM-1 can be detected shortly after ischemic or 
nephrotoxic injury in the urine and, therefore, may be an easily tested 
biomarker in the clinical setting.
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Neutrophil gelatinase associated lipocalin (NGAL, also known as 
lipocalin-2 or siderocalin) is another leading novel biomarker of AKI. 
NGAL can bind to iron siderophore complexes and may have tissue-
protective effects in the proximal tubule. NGAL is highly upregulated 
after inflammation and kidney injury and can be detected in the plasma 
and urine within 2 hours of cardiopulmonary bypass–associated    
AKI.
112-117 
MANAGEMENT OF ACUTE KIDNEY INJURY 
The management of individuals with and at risk for AKI varies 
according to the underlying cause. Common to all are several principles. 
Optimization of hemodynamics, correction of fluid and electrolyte 
imbalances, discontinuation of nephrotoxic medications, and dose 
adjustment of administered medications are all critical. Common causes 
of AKI such as sepsis and ischemic ATN, do not yet have specific 
therapies once injury is established, but meticulous clinical attention is 
needed to support the patient until (if) AKI resolves. The kidney 
possesses remarkable capacity to repair itself after even severe, dialysis-
requiring AKI. However, some patients with AKI do not recover fully 
and may remain dialysis dependent. 
 
INDICATIONS AND MODALITIES OF DIALYSIS 
Dialysis does not hasten recovery from AKI. Similarly, there is no 
consensus on the optimal renal replacement therapy in AKI. The 
preferred mode of renal replacement therapy is an area of active research.
 
The claimed superiority of the continuous renal replacement techniques 
remains unproven. Neither are there evidenced-based guidelines on the 
initiation of dialysis in AKI. Absolute indications for the commencement 
of renal replacement therapy include symptomatic uremia (asterixis, 
pericardial rub, encephalopathy) and acidosis, hyperkalemia, or volume 
overload that proves refractory to medical management. However, in 
clinical practice, most nephrologists initiate renal replacement therapy 
(RRT) before the onset of overt metabolic disarray when the need for 
renal support appears inevitable.  
The choice of dialysis modality (peritoneal dialysis, hemodialysis, 
or hemofiltration) is often guided by the resources of the health care 
institution, the technical expertise of the physician and the clinical status 
of the patient. The best time to start renal replacement therapy is 
controversial because the only studies linking timing with outcome are 
observational. Three forms of renal replacement therapy are available: 
continuous, intermittent (either as intermittent haemodialysis or slow low 
efficiency dialysis), and peritoneal dialysis.  
Peritoneal Dialysis 
Peritoneal dialysis in AKI is effected through a temporary 
intraperitoneal catheter. With the development of intermittent 
hemodialysis, and more recently, the slow continuous blood purification 
therapies, there has been a decline in the use of peritoneal dialysis in the 
acute setting.
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 It is still used in the treatment of AKI in regions where 
access to acute intermittent or slow continuous hemodialysis is not 
possible. Solute clearance and control of metabolic disarray in critically 
ill patients may be inferior to continuous veno-venous hemofiltration, and 
this has been associated with an adverse outcome in infection-associated 
AKI.  
Hemodialysis 
Acute intermittent hemodialysis has been the mainstay of renal 
replacement therapy in AKI over the past 40 years.
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 Typically, patients 
undergo dialysis for 3 to 4 hours daily or on alternate days depending on 
their catabolic state. The major complications of acute intermittent 
hemodialysis relate to rapid shifts in plasma volume and solute 
composition, the angioaccess procedure, and the necessity for 
anticoagulation. Intradialytic hypotension is common in patients 
undergoing acute intermittent hemodialysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
OUTCOME 
The crude mortality rate among patients with intrinsic AKI 
approximates 50% and has changed little over the past 3 decades.
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Mortality rates differ markedly depending on the cause of AKI: being 
approximately 15% in obstetric patients, 30% in toxin-related AKI, and 
60% to 90% in patients with sepsis.
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Although it was once widely held 
that the provision of effective renal replacement therapy largely corrected 
the prognostic import of an episode of AKI, more recent observations 
clearly demonstrate that this is not and probably never was the case, and 
that all too often, the development of AKI directly contributes to poor 
patient outcomes. Factors associated with a poor prognosis include male 
sex, advanced age, oliguria (<400 mL/day), and a rise in the serum 
creatinine value of greater than 3 mg/dL, factors reflecting more severe 
renal injury and failure of other organ systems. 
Even mild decreases in renal function are now recognized as being 
associated with worse patient outcomes. Even with the use of renal 
replacement therapy, mortality remains elevated as compared with those 
with maintained independent renal function.
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In addition to its clinical consequences, AKI prolongs hospital 
stays and is associated with substantially increased medical    
expenditure.
 126-128
  
Most patients who survive an episode of AKI regain independent 
renal function. However, 50% have subclinical functional defects. AKI is 
irreversible in approximately 5% of patients, usually as a consequence of 
complete cortical necrosis, and requires long-term renal replacement 
therapy with dialysis or transplantation. An additional 5% of patients 
suffer progressive deterioration in renal function after an initial recovery 
phase, probably because of hyperfiltration and subsequent sclerosis of 
remnant glomeruli. 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
 
1. To study the incidence of AKI in the medical wards of our hospital 
2. To study the etiological profile of AKI in medical wards 
3. To apply the AKIN criteria in AKI patients admitted to the medical 
wards and to confirm its significance 
4. To study the requirement of renal replacement therapy in AKI 
5. To study the outcomes of AKI 
6. To study the risk and prognostic factors of AKI 
 
 
 
 
 
MATERIALS AND METHODS 
 
Settings 
The study was conducted at the medical wards of Govt Rajaji 
Hospital, Madurai. 
Design of study 
Cross sectional study 
Period of study 
6 months 
Collaborating Department 
Departments of Nephrology 
Ethical clearance 
Approval obtained from Ethical Committee headed by Dean, Govt. 
Rajaji Hospital, Madurai 
Consent 
Informed consent obtained from all patients 
Data collection 
Clinical and biochemical data 
Conflict of interest 
Nil  
Financial support 
Nil  
TERMINOLOGY AND DEFENITIONS 
AKI was defined and classified by the AKIN criteria. 
Diagnostic criteria for acute kidney injury: An abrupt (within 48 
hours) reduction in kidney function currently defined as an absolute 
increase in serum creatinine of more than or equal to 0.3 mg/dl (≥ 26.4 
μmol/l), a percentage increase in serum creatinine of more than or equal 
to 50% (1.5-fold from baseline), or a reduction in urine output 
(documented oliguria of less than 0.5 ml/kg per hour for more than six 
hours). 
 
 
 
Classification/staging system for acute kidney injury 
Stage Serum creatinine criteria Urine output criteria 
1 Increase in serum creatinine of more 
than or equal to 0.3 mg/dl or increase 
to more than or equal to 150% to 200% 
(1.5- to 2-fold) from baseline 
Less than 0.5 ml/kg 
per hour for more than 
6 hours 
2 Increase in serum creatinine to more 
than 200% to 300% (> 2- to 3-fold) 
from baseline 
Less than 0.5 ml/kg 
per hour for more than 
12 hours 
3 Increase in serum creatinine to more 
than 300% (> 3-fold) from baseline (or 
serum creatinine of more than or equal 
to 4.0 mg/dl with an acute increase of 
at least 0.5 mg/dl, individuals who 
receive RRT) 
Less than 0.3 ml/kg 
per hour for 24 hours 
or anuria for 12 hours 
 
When baseline creatinine was not available, it was derived using 
the four-variable MDRD equation by assuming a baseline glomerular 
filtration rate (GFR) of 90 mL/min/1.73 m2. Oliguric renal failure was 
defined as urine output <400 mL/24hrs. 
Sepsis was defined as two or more of the following as a result of 
proven or suspected infection: (a) temperature > 38C or <36C, (b) heart 
rate >90/min, (c) respiratory rate >24/min, (d) W.B.C count >12,000/uL, 
<4000/uL, or > 10% band forms. 
Tropical febrile illness was defined as fever for 5–21 days without 
an obvious focus of infection (such as lower respiratory tract infection or 
urinary tract infection). 
Acute glomerulonephritis was considered in a case with clinical 
and biochemical markers substantiating the diagnosis. 
Drugs were identified as a cause of AKI when there was a temporal 
relationship to administration of drugs in the absence of other pathogenic 
mechanisms. 
Regarding the outcome, complete recovery was defined as the 
serum creatinine < 1.6mg/dL at the time of discharge. Partial recovery 
was defined as persistent dialysis-independent renal failure. The third 
outcome was in hospital mortality. 
 
PATIENT POPULATION 
Consecutive medical ward in-patients of GRH who were diagnosed 
to have AKI as per AKIN Criteria were enrolled in the study after 
informed consent. 
 
 
EXCLUSION CRITERIA 
Age < 13yrs 
Pre-existing renal disease 
Small contracted kidneys in USG 
Obstructive uropathy 
  
METHODS 
Detailed history, clinical examination and laboratory investigation 
were carried out in all patients. Following important data were recorded: 
date when AKI was detected, date of nephrology consultation, type and 
frequency of dialytic support instituted. Also, exposure to nephrotoxic 
drugs prior to or during hospital stay, co-morbid conditions, and base line 
serum creatinine were noted if available. All patients were subjected to 
urine analysis, hemogram, blood biochemistry (which included urea, 
creatinine, electrolytes, calcium, and phosphorus).USG was done to rule 
out CKD and obstructive causes. 
Renal replacement therapy (RRT) was done in patients with 
symptomatic uremia, serum creatinine > 4 mg/dL, fluid overload, severe 
metabolic acidosis and hyperkalemia unresponsive to conservative 
measures. 
The modalities of RRT were intermittent haemodialysis (HD), and 
intermittent peritoneal dialysis (PD). 
  The outcome was assessed and all the parameters were compared 
with outcome. 
 
STATISTICS 
Statistical analysis was performed with Chi-square analysis. A p 
value < 0.05 was considered significant. Data were expressed as Mean + 
1SD. 
 
 
 
 
 
 
 
 
 
OBSERVATIONS AND RESULTS 
 
In this study, 112 cases of AKI were studied in the medical wards 
of Government Rajaji hospital, Madurai during the study period. The 
following observations were noted. 
INCIDENCE 
Of the 4304 patients admitted to the medical wards during the 
study period, 112 patients (2.6%) were found to have AKI as per the 
inclusion and exclusion criteria. The incidence of AKI in medical wards 
was found to be 2.6%. 
PATIENT CHARACTERISTICS 
The age ranges between 42.4 + 15.55 years.  Median age was 40 
yrs. 
Almost 50% of our patients were in the 3
rd
 and 4
th
 decades (Fig.1). 
As we have not included pre-existing CKD in our study, age group > 50 
yrs have low incidence. 
Out of 112 patients, 70 (62.5 %) were males while 42 (37.5%) 
were females (Fig.2). The sex ratio is 1.6:1 
AGE AND GENDER DISTRIBUTION 
 
 GENDER 
FEMALE MALE TOTAL 
No % No % No % 
13 - 20 yrs 0 0.0% 8 7.1% 8 7.1% 
21 - 30 yrs 8 7.1% 10 8.9% 18 16.1% 
31 - 40 yrs 14 12.5% 20 17.9% 34 30.4% 
41 - 50 yrs 11 9.8% 12 10.7% 23 20.5% 
51 - 60 yrs 4 3.6% 10 8.9% 14 12.5% 
> 60 yrs 5 4.5% 10 8.9% 15 13.4% 
 
 
 
 
 
 
 
 
 
CLINICAL FEATURES 
The clinical features observed in our study were oliguria (65.2%), 
vomiting (61.6%), loose stools (50.9%), uremic symptoms (24.1%) 
breathlessness (17.9%), altered sensorium (10.7%), jaundice (9.8%), and 
edema (8.9%). Clinical features depend on the underlying condition and 
its severity. 
 
CLINICAL FEATURES OF AKI 
 
GENDER 
FEMALE MALE Total 
No. % No. % No. % 
LOOSE STOOLS PRESENT 21 18.8% 36 32.1% 57 50.9% 
VOMITING PRESENT 26 23.2% 43 38.4% 69 61.6% 
URINE OUTPUT 
OLIGURIC 
 
20 17.9% 53 47.3% 73 65.2% 
NON-
OLIGURIC 
22 19.6% 17 15.2% 39 34.8% 
BREATHLESSNE
SS 
PRESENT 8 7.1% 12 10.7% 20 17.9% 
ALTERED 
SENSORIUM 
PRESENT 6 5.4% 6 5.4% 12 10.7% 
EDEMA PRESENT 3 2.7% 7 6.2% 10 8.9% 
UREMIC 
SYMPTOMS 
PRESENT 8 7.1% 19 17.0% 27 24.1% 
JAUNDICE PRESENT 3 2.7% 8 7.1% 11 9.8% 
 
URINE VOLUME 
 
 
URINE VOLUME 
 Frequency Percent 
 
OLIGURIC 73 65.2 
NON-OLIGURIC 39 34.8 
Total 112 100.0 
 
 
 
Urine volume of each patient was charted. Out of 112 patients, 73 
patients (65.2%) had oliguric AKI while 39 patients had non-oliguric 
AKI (Fig.4). 
 
 
 
 
 
 
 
CO-MORBIDITIES 
 
 
 
CO-MORBIDITIES 
 Frequency Percent 
 
ABSENT 91 81.3 
HTN 6 5.4 
DM 10 8.9 
CAD 3 2.7 
CVA 1 .9 
COPD 1 .9 
Total 112 100.0 
 
 
Co-morbidities were absent in 81.3% patients (Fig.5). Out of the 21 
patients with co-morbidities, diabetes was present in 10 patients (8.9%), 
hypertension was present in 6 patients (5.4%) and CAD was present in 3 
patients (2.7%). CVA and COPD were present in 1 patient each. 
 
ETIOLOGY 
The most common cause of AKI was acute diarrheal disease 
(50%), followed by snake bite (21.4 %), sepsis (10.7 %), tropical acute 
febrile illness (7.1%), and glomerulonephritis (3.6%) (Fig.6). 
 
ETIOLOGICAL PROFILE OF AKI 
 GENDER 
FEMALE MALE Total 
No. % No. % No. % 
 
Acute Diarrheal Disease 20 17.9% 36 32.1% 56 50.0% 
Snake Bite 8 7.1% 16 14.3% 24 21.4% 
Sepsis 5 4.5% 7 6.2% 12 10.7% 
Tropical Acute Febrile 
Illness 
3 2.7% 5 4.5% 8 7.1% 
Acute Glomerulonephritis 1 0.9% 3 2.7% 4 3.6% 
NSAID Induced 0 0.0% 1 0.9% 1 0.9% 
Super Vasmol Poisoning 3 2.7% 0 0.0% 3 2.7% 
Copper Sulphate 
Poisoning 
1 0.9% 1 0.9% 2 1.8% 
Pigment Nephropathy 1 0.9% 1 0.9% 2 1.8% 
 
  
ETIOLOGICAL PROFILE OF AKI : AGE WISE 
 AGE 
13 - 20 
yrs 
21 - 30 
yrs 
31 - 40 
yrs 
41 - 50 
yrs 
51 - 60 
yrs 
> 60 
yrs 
No. No. No. No. No. No. 
 
Acute Diarrheal Disease 4 8 17 10 7 10 
Snake Bite 2 4 10 5 1 2 
Sepsis 0 1 1 5 3 2 
Tropical  Acute Febrile 
Illness 
1 0 2 2 3 0 
Acute Glomerulonephritis 1 3 0 0 0 0 
NSAID Induced 0 0 0 0 0 1 
Super Vasmol Poisoning 0 2 1 0 0 0 
Copper Sulphate Poisoning 0 0 1 1 0 0 
Pigment Nephropathy 0 0 2 0 0 0 
 
 
 
 
MEAN VALUES OF LABORATORY FEATURES 
 
 
Characteristics Mean Standard deviation 
Hemoglobin 9.88 1.65 
Urea 97.04 48.35 
Creatinine 4.59 2.96 
 
 
 
 
 
 
 
 
 
 
 
 
AKIN STAGE 
Of the 112 patients, 32 (28.6%), 21 (18.8%) and 59 (52.7%) were 
in the AKIN 1, AKIN 2 and AKIN 3 stages respectively (Fig.7). 
 
 
AKIN STAGE DISTRIBUTION 
 AKIN STAGE 
AKIN 1 AKIN 2 AKIN 3 
No. % No. % No. % 
 
Acute Diarrheal Disease 17 30.4% 13 23.2% 26 46.4% 
Snake Bite 8 33.3% 2 8.3% 14 58.3% 
Sepsis 2 16.7% 3 25.0% 7 58.3% 
Tropical  Acute Febrile 
Illness 
1 12.5% 1 12.5% 6 75.0% 
Acute Glomerulonephritis 2 50.0% 1 25.0% 1 25.0% 
NSAID Induced 0 0.0% 0 0.0% 1 100.0% 
Super Vasmol Poisoning 2 66.7% 0 0.0% 1 33.3% 
Copper Sulphate Poisoning 0 0.0% 1 50.0% 1 50.0% 
Pigment Nephropathy 0 0.0% 0 0.0% 2 100.0% 
 
 
 
 
TIMING OF DIAGNOSIS  
 
 
DIAGNOSIS OF AKI 
 Frequency Percent 
 
ON ADMISSION 50 44.6 
AFTER 
ADMISSION 
62 55.4 
Total 112 100.0 
 
 
DIAGNOSIS OF AKI 
 AKIN STAGE 
AKIN 1 AKIN 2 AKIN 3 
No. % No. % No. % 
 
ON ADMISSION 13 26.0% 7 14.0% 30 60.0% 
AFTER 
ADMISSION 
19 30.6% 14 22.6% 29 46.8% 
 
 
    Of the 112 patients who developed AKI, 50 (44.6%) were detected to 
have AKI at the time of admission [AKIN: STAGE 1, 13 (26%); STAGE 
2, 7 (14%); and STAGE 3, 30(60%)] and 62 (55.4%) developed AKI 
after admission [AKIN: STAGE 1, 19 (30.6%); STAGE 2, 14 (22.6%); 
and STAGE 3, 29 (46.8%)] (Fig.8). 
MANAGEMENT 
Dialysis was done as per the indications. In all, 35 patients (31.25 
%) required dialytic support (Fig.9), of which 27 (24.1%) were treated by 
hemodialysis and 8 (7.1%) by peritoneal dialysis. The remaining 77 
patients (68.8%) were treated conservatively (Fig.10). The commonest 
indication for dialysis was symptomatic uremia. 
 
 
REQUIREMENT OF RRT 
 RRT REQUIRED 
YES NO 
No. % No. % 
 
Acute Diarrheal Disease 13 23.2% 43 76.8% 
Snake Bite 11 45.8% 13 54.2% 
Sepsis 5 41.7% 7 58.3% 
Tropical  Acute Febrile 
Illness 
2 25.0% 6 75.0% 
Acute Glomerulonephritis 1 25.0% 3 75.0% 
NSAID Induced 0 0.0% 1 100.0% 
Super Vasmol Poisoning 1 33.3% 2 66.7% 
Copper Sulphate 
Poisoning 
0 0.0% 2 100.0% 
Pigment Nephropathy 2 100.0% 0 0.0% 
 
 MANAGEMENT OF AKI 
 RRT TYPE 
CONSERVATIVE HEMO-
DIALYSIS 
PERITONEAL-
DIALYSIS 
No. % No. % No. % 
 
Acute Diarrheal Disease 43 38.4% 9 8.0% 4 3.6% 
Snake Bite 13 11.6% 9 8.0% 2 1.8% 
Sepsis 7 6.2% 3 2.7% 2 1.8% 
Tropical  Acute Febrile 
Illness 
6 5.4% 2 1.8% 0 0.0% 
Acute 
Glomerulonephritis 
3 2.7% 1 0.9% 0 0.0% 
NSAID Induced 1 0.9% 0 0.0% 0 0.0% 
Super Vasmol Poisoning 2 1.8% 1 0.9% 0 0.0% 
Copper Sulphate 
Poisoning 
2 1.8% 0 0.0% 0 0.0% 
Pigment Nephropathy 0 0.0% 2 1.8% 0 0.0% 
 
                          
                         
DURATION OF HOSPITAL STAY 
The mean duration of hospital stay was 9.2 + 4.44 days. 
 
OUTCOME 
Regarding the outcome of AKI, 93 patients (83%) had complete 
recovery and 7 patients (6.2%) had partial recovery. The overall in-
hospital mortality rate was 10.7% (Fig11). 
 
OUTCOME OF AKI 
 No. % 
OUTCOME 
COMPLETE 
RECOVERY 
93 83.0% 
PARTIAL 
RECOVERY 
7 6.2% 
IN-HOSPITAL 
MORTALITY 
12 10.7% 
 
 
 
 
AGE AND OUTCOME 
 
 
AGE AND OUTCOME 
 OUTCOME 
RECOVERY IN-HOSPITAL 
MORTALITY 
No. % No. % 
AGE 
13 - 20 yrs 7 87.5% 1 12.5% 
21 - 30 yrs 18 100.0% 0 0.0% 
31 - 40 yrs 32 94.1% 2 5.9% 
41 - 50 yrs 18 78.3% 5 21.7% 
51 - 60 yrs 12 85.7% 2 14.3% 
> 60 yrs 13 86.7% 2 13.3% 
 
P 0.278 
 
Mortality was more in the age group of 41 –50 yrs (21.7%) while it 
is less in the age group of 31- 40 yrs (5.9%). So as the age advances, 
there is increase in mortality. Mortality appears to be less in patients 
above 50 years. This may be due to exclusion of CKD patients. 
GENDER AND OUTCOME 
 
 
GENDER AND OUTCOME 
 OUTCOME 
RECOVERY IN-HOSPITAL 
MORTALITY 
No. % No. % 
GENDER 
FEMALE 37 88.1% 5 11.9% 
MALE 63 90.0% 7 10.0% 
 
P 0.849 
 
Mortality was more in females (11.9%) than males (10.0%).  
 
 
 
 
 
 
 
CO-MORBIDITIES AND OUTCOME 
 
 
CO-MORBIDITIES AND OUTCOME 
 OUTCOME 
RECOVERY IN-HOSPITAL 
MORTALITY 
No. % No. % 
 
ABSENT 84 92.3% 7 7.7% 
HTN 6 100.0% 0 0.0% 
DM 6 60.0% 4 40.0% 
CAD 2 66.7% 1 33.3% 
CVA 1 100.0% 0 0.0% 
COPD 1 100.0% 0 0.0% 
 
P 0.186 
 
Among co-morbidities, mortality was more in patients with diabetes 
(40%) and CAD (33.3%). 
 
 
 
 
 
ETIOLOGY AND OUTCOME 
 
ETILOGY AND OUTCOME 
 OUTCOME 
RECOVERY IN-HOSPITAL 
MORTALITY 
No. % No. % 
 
Acute Diarrheal Disease 55 98.2% 1 1.8% 
Snake Bite 24 100.0% 0 0.0% 
Sepsis 5 41.7% 7 58.3% 
Tropical  Acute Febrile 
Illness 
6 75.0% 2 25.0% 
Acute Glomerulonephritis 4 100.0% 0 0.0% 
NSAID Induced 1 100.0% 0 0.0% 
Super Vasmol Poisoning 2 66.7% 1 33.3% 
Copper Sulphate Poisoning 1 50.0% 1 50.0% 
Pigment Nephropathy 2 100.0% 0 0.0% 
 
P 0.000 
 
Sepsis induced AKI had the highest in hospital mortality of 58.3%. 
URINE VOLUME AND OUTCOME 
 
 
URINE VOLUME AND OUTCOME 
 OUTCOME 
RECOVERY IN-HOSPITAL 
MORTALITY 
No. % No. % 
 
OLIGURIC 63 86.3% 10 13.7% 
NON-OLIGURIC 37 94.9% 2 5.1% 
 
P 0.039 
 
Mortality was greater in oliguric AKI (13.7%) than in non-oliguric 
AKI (5.1%). This is probably due to the increased severity of the insult in 
oliguric AKI. 
 
 
 
 
 
AKIN STAGE AND OUTCOME 
 
 
AKIN STAGE AND OUTCOME 
 OUTCOME 
RECOVERY IN-HOSPITAL 
MORTALITY 
No. % No. % 
 
AKIN 1 32 100.0% 0 0.0% 
AKIN 2 19 90.5% 2 9.5% 
AKIN 3 49 83.1% 10 16.9% 
 
P 0.007 
 
Mortality in AKIN stages were 0.0%, 9.5%, and 16.9% 
respectively for stage 1, stage 2 and stage 3. Thus, as the severity of AKI 
increases, mortality also increases.  
 
 
 
 
TIMING OF DIAGNOSIS AND OUTCOME 
 
 
TIMING OF DIAGNOSIS AND OUTCOME 
 OUTCOME 
RECOVERY IN-HOSPITAL 
MORTALITY 
No. % No. % 
 
ON ADMISSION 45 90.0% 5 10.0% 
AFTER ADMISSION 55 88.7% 7 11.3% 
 
P 0.969 
 
Mortality was more in patients who developed AKI after admission 
to hospital (11.3%) 
 
 
 
 
 
 
DIALYSIS REQUIREMENT AND OUTCOME 
 
 
DIALYSIS REQUIREMENT  AND OUTCOME 
 OUTCOME 
RECOVERY IN-HOSPITAL 
MORTALITY 
No. % No. % 
RRT 
REQUIRED 
YES 30 85.7% 5 14.3% 
NO 70 90.9% 7 9.1% 
 
P 0.000 
 
Mortality is more in patients who underwent dialysis (14.3%) than 
in patients who were treated conservatively (9.1%). Thus dialysis does 
not improve the outcome of patients with AKI. 
 
 
 
 
 
DISCUSSION 
INCIDENCE 
The incidence of AKI is difficult to estimate because no registry of 
its occurrence exists and because up until recently there was no 
standardized definition. From a variety of predominantly single centre 
studies it is estimated that 5% to 7% of hospitalized patients develop 
AKI.
33-36 
In our study, the incidence of AKI was 2.6%. This is in 
concordance with a previous study done by Kaul et al
129
 in North India in 
which the incidence of AKI was 2.5%. 
AGE 
Almost 50% of our patients were in the 3
rd
 and 4
th
 decades. Age 
group 13 to 20 yrs had the least incidence. The mean age of the 
population was 42.4 + 15.55 years.  Median age was 40 yrs. Only 13.4% 
patients were more than 60 yrs of age. This implies the occurrence of 
AKI in the younger age groups as compared with developed countries. In 
a country like India where access to health care insurance is limited, AKI 
in middle aged population creates a huge economic burden on the 
families.  
SEX 
In our study, out of 112 patients, 70 (62.5 %) were males while 42 
(37.5%) were females. 
CLINICAL FEATURES 
The common clinical features were oliguria (65.2%), vomiting 
(61.6%), loose stools (50.9%), and uremic symptoms (24.1%). Edema 
was the least common symptom present in 8.9%. This means that most of 
our patients presented early in the course of illness. This also reflects the 
adequacy of referral services. 
Based on urine volume, patients were classified into oliguric and 
non-oliguric groups. In our study, oliguric AKI predominates (65.18%). 
This is in concordance with a previous study Muthusethupathi et al.
130 
CO-MORBIDITIES
 
Co-morbidities were present in 18.7% of patients. Diabetes was the 
commonest (8.9%), followed by hypertension (5.4%) and CAD (2.7%). 
ETIOLOGY 
Acute diarrhoeal disease was the leading cause of AKI in our study 
accounting for 50 % of cases. This is despite an improvement in hygiene, 
socioeconomic and living conditions and a greater stress on rehydration 
therapies. This may be in part due to a lack of awareness on the part of 
general practitioners, delays in correction of fluid and electrolyte losses, 
and late referral.
18
Although there seems to be a decline in AKI due to 
diarrhoeal disease reported from other centers,
18 
such a pattern was not 
observed here. 
In our study, AKI due to ADD was most common in the 3
rd
 decade 
(30.3%). Males (64.2%) were commonly affected by ADD than females. 
Because they are the bread winners of the family, they are used to 
consuming outside food. 
AKIN stage distribution of ADD: Stage 1, 17(30.4%); Stage 2, 
13(23.2%); Stage 3, 26 (46.4%). 
Of 56 patients with AKI due to ADD, 13 (23.2%) were treated with 
dialysis. The remaining 43 patients (76.8%) were treated conservatively. 
The mortality observed during the study was 1.8%.  
Jayakumar et al
132
 in their study from Chennai reported that ADD 
was the commonest cause of AKI (28.6%). The mortality was 8.7% and 
requirement of RRT was 66.1%. 
Kaul et al
129
 in their study reported that 29 % cases of AKI in 
North India were due to diarrhoeal diseases. Mortality was 14.8% and 
requirement of RRT was 72.2%. 
 
AKI following snake bite is a major problem in rural India, 
contributing to 21.4 % of AKI cases in our study. This is comparable to 
other reported series from India (13-32%).
444
  
AKI due to snake bite also was also common in the 3
rd
 decade 
(41.6%) and in males (66.6%). Males are the bread winners of the family. 
They indulge in agricultural work without adequate use of protective 
footwear. This may be reason for the above finding. 
AKIN stage distribution of snake bite: Stage 1, 8(33.3%); Stage 2, 
2(8.3%); Stage 3, 14 (58.3%). 
Of the 24 patients with snake bite AKI, 11(45.8%) were treated 
with dialysis. There was no mortality observed during the study. 
Athappan et al
133
 in their study from Madurai reported the 
prevalence of AKI in snake bite to be 13.5%. In this study, the 
requirement of RRT was 45.3% and the mortality observed was 22.5%. 
According to this study, the risk factors for development of AKI were 
cellulitis and regional lymphadenopathy, while the predictors of poor 
outcome were hypotension and bleeding. 
Sweni et al
134
 in their study from Chennai reported a prevalence of 
AKI in snake bite of 7%. 
Jayakumar et al
132
 in their study reported that 7.8% of cases of 
AKI were due to snake bite. The requirement of RRT in this study was 
94.2%. As the study was done in a tertiary referral centre, most patients 
were referred late with renal failure. They reported a mortality of 27.5%. 
Sepsis is the emerging cause of AKI. It accounted for 10.7% of 
cases of AKI in our study. AKI due to sepsis were common in the 4
th
 
(41.6%) and 5
th
 decades (25%). 
AKIN stage distribution of sepsis induced AKI: Stage 1, 2(16.7%); 
Stage 2, 3(25%); Stage 3, 7 (58.3%). 
 Sepsis induced AKI had the highest in-hospital mortality of 
58.3%, which is similar to data from other Indian centres. It may be due 
to an association with co-morbid illnesses (Diabetes), and higher 
incidence of multi organ dysfunction syndrome in these patients. Thus 
sepsis- induced AKI was among the worst prognostic group.  
Worldwide, the incidence of sepsis related AKI is increasing. AKI 
represents an independent risk factor for mortality in these patients. The 
requirement of dialysis in our study was 41.7%. 
Jayakumar et al
132
 reported the incidence of sepsis related AKI to 
be 8.8%. The requirement of RRT was 78.5% and mortality was 56.1%. 
Kaul et al
129 
reported a mortality of 46.1% and need for dialysis of 
92.3% for sepsis related AKI. 
Tropical acute febrile illnesses are a common cause of AKI in the 
developing countries. In Southern India, the common tropical acute 
febrile illness among hospitalized patients included malaria, typhoid, 
scrub typhus, dengue, leptospirosis, spotted fever and others. In our 
study, tropical acute febrile illnesses accounted for 7.14% of AKI. Out of 
8 patients, 6 (5.3%) were due to leptospirosis. For the remaining 2 
patients (1.7%) the aetiology of fever could not be ascertained.  
AKIN stage distribution of tropical acute febrile illness induced 
AKI: Stage 1, 1(12.5%); Stage 2, 1(12.5%); Stage 3, 6 (75%). 
       Two patients (25%) with leptospirosis required dialysis, both had 
in-hospital mortality (25%). 
Basu et al
135
 in a study from Vellore reported a 3.9 % incidence of 
AKI in leptospirosis. There was no mortality or requirement for dialysis. 
The incidence of leptospirosis in this study was lower than that observed 
in centres with humid, marshy environment and higher rainfall.
136
 
Jayakumar et al
132
 reported a 7.5% incidence of AKI in 
leptospirosis. 53.5% of patients required dialysis and mortality was 9.5%. 
Kaul et al
129 
reported an incidence of 6.25% of leptospirosis 
related AKI. 
There has been a dramatic reduction in the incidence of leptospiral 
AKI. Leptospirosis was once the most common cause of AKI in this part 
of India
130
. Whether this reduced incidence is real or due to greater 
awareness, better diagnostic facilities, and/or the widespread use of 
empirical penicillin is not clear. 
In the last decade, malaria has returned to many places from where 
it was said to have been eradicated. India contributes 80% of all cases of 
malaria in Southeast Asia. Although falciparum infection remains the 
most common cause of complicated malaria, various Indian investigators 
have documented the increased incidence of complicated malaria in vivax 
infections. AKI due to falciparum malaria has been reported mostly from 
Southeast Asia and Africa. Malarial AKI has not been reported in the 
current study. 
No cases were also reported by Muthusethupathi et al
130
. 
Jayakumar et al
132
 reported a 4.4% incidence of AKI, mostly 
(93.8%) due to plasmodium falciparum. Plasmodium vivax was also 
observed in 6.2% of malarial AKI. Dialysis was required in 77.5% and 
mortality was 26.5%. 
Kaul et al
129 
reported an incidence of malarial AKI of 18.8%. Need 
for dialysis was 88.6% and mortality was 20%. 
Basu et al
135
 in their study reported that falciparum malaria (pure 
and mixed, respectively) had the highest incidence of AKI (63.2% and 
54.2%). Mortality was much lower (13.2% and 4.2%) compared with the 
other acute febrile illnesses. Requirement of RRT was 23.7% and 16.7% 
respectively. Probably due to early diagnosis and effective treatment, the 
mortality was much lower. All patients who died had AKI, making it an 
important risk factor for mortality. 
In our study, 4 patients (3.6%) had acute glomerulonephritis. AKI 
due to AGN is most common in the 3
rd
 decade (75%). 
AKIN stage distribution of AGN induced AKI: Stage 1, 2(50%); 
Stage 2, 1(25%); Stage 3, 1 (25%). 
              One patient was treated with HD (25%). All patients recovered. 
Jayakumar et al
132
 reported the incidence of AGN related AKI to 
be 9.3%. The requirement of RRT was 84.6% and mortality was 21.1%. 
Crescentic glomerulonephritis, followed by post-infectious proliferative 
glomerulonephritis, SLE, and IgA nephropathy (in order of frequency), 
accounted for the cases. 
Kaul et al
129 
reported an incidence of AGN related AKI of 6.45%. 
Need for dialysis was 66.7% and mortality was 25%. 
Drugs are a common cause of AKI. In our study only patient 
(0.9%) had NSAID induced AKI. He was managed conservatively. 
Jayakumar et al
132
 reported that drugs were the second most 
common cause of AKI. Unknown analgesic combinations were the most 
common reason for admission due to drug-induced AKI, followed by 
Rifampicin and NSAIDS. Rifampicin-induced AKI was noted to occur 
frequently in patients who received intermittent therapy. 
Kaul et al
129 
reported an incidence of drug induced AKI of 6.45%. 
Need for dialysis was 77.8% and mortality was 22.2%. 
AKI due to Super Vasmol poisoning contributed 2.7% and that due 
to copper sulphate poisoning contributed 1.8% in our study. All cases of 
Super Vasmol poisoning occurred in females. Suicidal tendency is more 
common in females than in males. 
Among 3 patients with Super Vasmol poisoning, one required 
dialysis in the form of HD (33.3%). The patient however had in-hospital 
mortality (33.3%). Among 2 patients with copper sulphate poisoning, 
both were treated conservatively, however one patient had in-hospital 
mortality. There were no cases of AKI due to rat killer poison in our 
study. 
Super Vasmol is now emerging as a major cause of suicidal 
poisoning in India.
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 Sahay et al
138
 reported that 0.6% of all AKI in their 
study was due to Super Vasmol. 
Sweni et al
134 
reported that amongst the chemical poisons, copper 
sulphate (10%) and rat killer (1.4%) were the commonest causes of AKI. 
Jayakumar et al
132
 in their study reported an incidence of 4.3% for 
copper sulphate induced AKI with a requirement of dialysis of 64.5% and 
mortality of 35.4%. 
No cases of Super Vasmol poisoning were reported by Jayakumar 
et al
132
 and Kaul et al.
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2 patients (1.8%) with AKI in our study were due to pigment 
nephropathy. Both patients required RRT in the form of HD. Both 
patients recovered. 
TIMING OF DIAGNOSIS  
55.4% patients developed AKI after admission. This may be due to 
two reasons. Either our treatment was ineffective, or we paid much 
attention to renal parameters.  
44.6% of patients had AKI on admission. Measures should be 
aimed at prevention of AKI. They are best initiated at the community and 
primary healthcare level rather than at a tertiary hospital level. 
DIALYSIS 
Literature regarding the modality of choice for dialysis is 
conflicting. There is no study which has conclusively demonstrated the 
appropriate type and dose of RRT in AKI.
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The percentage of patients 
with AKI who required dialysis was 31.25 %.  
Among the common causes of AKI, the requirement of dialysis 
was more with snake bite (45.8%) than with ADD (23.2%). Thus snake 
bite needs more intensive treatment than ADD because of infection, 
hemolysis and anemia. 
Of the dialytic modalities, hemodialysis was the most commonly 
used. 27 patients (24.1%) were treated by hemodialysis. Peritoneal 
dialysis was used in 8 patients (7.1%). Although HD is the dialytic 
modality of choice in many centres, PD because of its easy availability 
and low cost remains a major dialytic modality in many hospitals. PD can 
also be used as a bridge therapy, avoiding the use of central catheters 
which can cause infectious complications. 
OUTCOME 
Mortality rates in AKI are variable, ranging from approximately 
7% among patients admitted to a hospital with prerenal AKI to more than 
80 percent among patients with postoperative AKI.
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 Mortality rate 
among patients with AKI have not decreased appreciably, despite major 
advances in dialysis and intensive care.
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This phenomenon can be 
explained by two demographic changes. Age of the patients is continuing 
to rise and increased incidence of coexisting serious illnesses among 
these patients. Most common causes of death with the advent of dialysis 
are sepsis, cardiopulmonary dysfunction, and the withdrawal of life-
support measures.
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In our study, 93 patients (83%) had complete recovery and 7 
patients (6.2%) had partial recovery. The in-hospital mortality in our 
study was 10.7%. In our study, mortality was more in patients in the 
fourth decade and in females. However both associations were not 
statistically significant. 
Among co-morbidities diabetes (40%) and CAD (33.3%) were 
associated with high mortality. This association was also not statistically 
significant. 
Mortality was greater in oliguric AKI (13.7%) than in non-oliguric 
AKI (5.1%). This is probably due to the increased severity of the insult in 
oliguric AKI. Thus in our study, oliguric AKI was an independent risk 
factor for mortality. This is concordant with many other studies.
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Sepsis induced AKI had the highest in-hospital mortality rate of 
58.3%. Among the general public, there is wide spread belief in non 
qualified and indigenous practitioners and quacks. There is also lack of 
medical facilities in rural areas. Along with poverty, these factors lead to 
delayed presentation of the patient to hospital with multiorgan 
dysfunction and sepsis which is associated with very high mortality. 
Mortality in AKIN stages were 0.0%, 9.5%, and 16.9% 
respectively for stage 1, stage 2 and stage 3. Thus, as the severity of AKI 
increases, mortality also increases.  
Mortality was more in patients who were diagnosed to have AKI 
after admission (11.3%) than in patients who were diagnosed on 
admission (10%). 
Mortality was more in patients who underwent dialysis (14.3%) 
than in patients who were treated conservatively (9.1%). Thus dialysis 
does not improve the outcome of patients with AKI. Although it was once 
widely held that the provision of effective renal replacement therapy 
largely corrected the prognostic importance of an episode of AKI, more 
recent observations clearly demonstrate that this is not and probably 
never was the case, and that all too often, the development of AKI 
directly contributes to poor patient outcomes. Even mild decreases in 
renal function are now recognized as being associated with worse patient 
outcomes. Even with the use of renal replacement therapy, mortality 
remains elevated as compared with those with maintained independent 
renal function.
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Mortality in patients with AKI were known to be high with coma, 
assisted respiration, hypotension, jaundice, prolonged renal failure, high 
entry serum creatinine, hypoalbuminemia, anemia, sepsis, severe co-
morbidities, multiorgan failure, and oliguria
12.
  Jayakumar et al
132
 
reported oliguria, high entry serum creatinine (>440 μmol), jaundice, 
sepsis, anemia, and hypoalbuminemia to be risk factors associated with 
mortality. 
AKI is a significant risk factor for mortality in these patients. 
Stratification based on the AKIN staging clearly demonstrates an 
incremental risk of primary end points such as mortality and RRT 
requirement. AKIN criteria, initially framed for ischemic AKI and 
validated in the western world among critically ill hospitalized patients,
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are equally valid and applicable to AKI in our setting. Apart from 
increased mortality, longer duration of hospital stay and the requirement 
of renal replacement therapy, the loss of the young workforce increases 
the economic burden. Using these criteria, it is now possible to identify 
patients at an early stage of AKI and study effective therapeutic or 
preventive measures. This can contain and prevent AKI, reducing 
morbidity and mortality, saving money and lives. 
 
 
 
 
 
 
 
 
CONCLUSIONS 
1. The incidence of AKI in the medical wards of G.R.H, Madurai was 
2.6%. The incidence correlates well with other studies. 
2. Clinical spectrum of AKI: 
 Most common age group was 30 to 40 yrs in this study 
 The incidence of AKI was more in males than females (1.6:1 
ratio) 
 Most common clinical features were oliguria (65.2%), vomiting 
(61.6%) and loose stools (50.9%) 
 Co-morbidities found in the decreasing order were DM, HTN 
and CAD 
 Oliguric AKI and non-oliguric AKI were seen in 65.2 % and 
34.8% respectively 
3. Etiology of AKI: Acute diarrheal disease (50%) was the most 
common cause of AKI, followed by snake bite (21.4 %), sepsis 
(10.7%), tropical acute febrile illness (7.1%), glomerulonephritis 
(3.6%). 
 Acute diarrhoeal disease still remains the most common cause 
of acute kidney injury. Mortality observed during the study is 
very low when compared the previous studies. Awareness of 
early rehydration therapy and early referral to higher centres 
contributed to decline in mortality. 
 Snake bite induced AKI is very high in our study compared to 
other studies 
 Leptospiral AKI is on the decline. Drugs and sepsis are 
emerging causes of AKI 
4. According to AKIN Criteria, 28.6%, 18.8% and 52.7% were in the 
AKIN 1, AKIN 2 and AKIN 3 stages respectively. 
5. 44.6% of patients were detected to have AKI on admission while 
55.4% developed AKI after admission. 
6. Requirement of dialytic support in our study was 31.25%, of which 
24.1% were treated by hemodialysis and 7.1% by peritoneal 
dialysis. 
7. Hemodialysis has become the preferred mode of renal replacement 
therapy. 
8. Outcome: 
 Complete recovery was seen in 83% cases and partial recovery 
was seen in 6.2% cases 
 In-hospital mortality rate was 10.7% 
 Sepsis induced AKI had the highest in-hospital mortality 
(58.3%) 
9. Risks and prognostic factors 
 Oliguric AKI was associated with increased mortality 
 Higher AKIN stage was associated with increased mortality 
 Dialysis requirement was associated with increased mortality 
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RIFLE classification scheme for acute renal failure. The 
classification system includes separate criteria for creatinine and 
urine output. A patient can fulfill the criteria through changes in 
serum creatinine (SCreat) or changes in urinary output, or both. The 
criteria that lead to the worst possible classification should be used. 
 
 
 
 
 
  
 
 
Organ cross-talk: Distant organ effects following ischemic acute 
kidney injury. Organ cross-talk can include the liver, heart, lungs, 
bone marrow, and gastrointestinal tract. 
 
 
 
 
 
 
 
  
 
 
 
 
 
Key potential pathways implicated in pathogenesis of acute kidney 
injury due to ischaemia or sepsis 
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sno age sex durstay diar vomit olig breath altsens edema neptox uremsym jaund comor hb crHI
1 50 FEMALE 15 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT PRESENT ABSENT ABSENT 11 11.7
2 40 FEMALE 14 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 8 5
3 55 MALE 15 PRESENT PRESENT OLIGURIC ABSENT ABSENT PRESENT ABSENT PRESENT ABSENT DM 10 7.5
4 65 MALE 0 PRESENT PRESENT OLIGURIC PRESENT PRESENT ABSENT ABSENT PRESENT ABSENT CAD 4 8.8
5 23 MALE 14 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT PRESENT ABSENT ABSENT 11 5.5
6 45 MALE 16 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT PRESENT ABSENT ABSENT 9 6
7 65 MALE 14 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT PRESENT ABSENT HTN 7 4.5
8 34 MALE 14 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT PRESENT ABSENT ABSENT 12 10
9 65 MALE 12 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT PRESENT ABSENT DM 10 9
10 35 MALE 13 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 8.5 7.6
11 64 FEMALE 16 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT PRESENT ABSENT DM 11 7
12 54 FEMALE 13 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT PRESENT ABSENT ABSENT 13.3 11
13 64 FEMALE 14 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 8 7.5
14 15 MALE 5 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 9 2.8
15 13 MALE 6 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 9 3.3
16 60 MALE 7 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 10 3
17 60 MALE 6 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT PRESENT ABSENT ABSENT 8.7 1.9
18 32 MALE 5 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 11 5.5
19 58 MALE 8 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 9 3.9
20 55 MALE 6 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 12.9 3.2
21 55 MALE 5 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT HTN 9.2 2.8
22 40 MALE 8 PRESENT ABSENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 8.4 2.2
23 35 MALE 6 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT PRESENT ABSENT ABSENT 8 2.4
24 40 MALE 5 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 7.8 3.6
25 35 MALE 8 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 8.1 3
26 65 MALE 7 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 8.7 1.9
27 73 MALE 6 PRESENT ABSENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT COPD 9.1 6
28 23 MALE 9 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 10 2.9
29 14 MALE 6 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 7.8 2.1
30 45 MALE 4 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 9 3.8
31 43 MALE 6 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 10 3.5
32 32 MALE 7 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 9 1.5
33 14 MALE 8 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT PRESENT ABSENT ABSENT 9.6 2.9
34 25 MALE 9 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 6.3 3.3
35 42 MALE 6 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 7 3.4
36 36 MALE 5 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 9.2 1.9
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37 28 MALE 7 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT PRESENT ABSENT ABSENT 11 2.2
38 29 MALE 8 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 8 3.1
39 39 MALE 9 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 10.2 4.8
40 49 MALE 8 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 9.8 1.6
41 62 MALE 6 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT PRESENT ABSENT CVA 10.8 3.3
42 35 FEMALE 6 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 10 5.2
43 32 FEMALE 6 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 5.9 2
44 75 FEMALE 7 PRESENT PRESENT OLIGURIC PRESENT PRESENT ABSENT ABSENT PRESENT ABSENT HTN 8.6 4.5
45 54 FEMALE 8 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 10.8 2.4
46 35 FEMALE 5 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 9.2 2.6
47 63 FEMALE 7 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 12 3.8
48 25 FEMALE 5 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT DM 9.7 5.5
49 36 FEMALE 6 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 9 1.8
50 57 FEMALE 5 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 8.8 3.2
51 63 FEMALE 8 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 10 3.5
52 26 FEMALE 6 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 10.8 3.4
53 29 FEMALE 9 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 7.9 1.5
54 36 FEMALE 5 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 11.9 2.1
55 72 FEMALE 6 PRESENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT HTN 6.7 6.3
56 35 FEMALE 7 PRESENT PRESENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT CAD 12.3 2.9
57 24 MALE 18 ABSENT ABSENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 10.2 12.5
58 37 MALE 7 ABSENT ABSENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 9.4 6.2
59 40 MALE 7 ABSENT ABSENT OLIGURIC PRESENT ABSENT PRESENT ABSENT ABSENT ABSENT ABSENT 8.6 5.4
60 19 MALE 13 ABSENT PRESENT OLIGURIC ABSENT PRESENT PRESENT ABSENT PRESENT ABSENT ABSENT 10 5.7
61 35 MALE 10 ABSENT ABSENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 12 10.7
62 38 MALE 19 ABSENT ABSENT OLIGURIC ABSENT ABSENT ABSENT ABSENT PRESENT ABSENT ABSENT 9.9 9
63 31 MALE 13 ABSENT ABSENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 11.6 8.6
64 38 MALE 15 ABSENT ABSENT OLIGURIC PRESENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 12 2.5
65 67 MALE 5 ABSENT ABSENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT DM 10 2.9
66 49 MALE 5 ABSENT ABSENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT HTN 9.2 4
67 75 MALE 6 ABSENT ABSENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT HTN 10.4 1.9
68 56 MALE 5 ABSENT ABSENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 8.6 3.6
69 45 MALE 6 ABSENT ABSENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 9.6 2.4
70 37 MALE 8 ABSENT ABSENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 11.8 2.2
71 28 MALE 6 ABSENT ABSENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 8.8 1.6
72 16 MALE 8 ABSENT ABSENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 10 1.8
73 27 FEMALE 7 ABSENT ABSENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT PRESENT ABSENT ABSENT 9.6 8.9
74 25 FEMALE 6 ABSENT ABSENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 9.8 10
75 41 FEMALE 9 ABSENT ABSENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 12.5 6
76 36 FEMALE 7 ABSENT ABSENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT PRESENT ABSENT ABSENT 10 4.3
77 37 FEMALE 6 ABSENT ABSENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 12 1.8
78 45 FEMALE 8 ABSENT ABSENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 9 3.2
79 56 FEMALE 7 ABSENT ABSENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 11.2 1.7
80 37 FEMALE 6 ABSENT ABSENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 8.9 2.3
81 45 MALE 0 ABSENT PRESENT OLIGURIC PRESENT PRESENT ABSENT ABSENT ABSENT PRESENT DM 11.9 5.5
82 50 MALE 0 ABSENT ABSENT OLIGURIC PRESENT PRESENT ABSENT ABSENT ABSENT ABSENT ABSENT 9.8 4.2
83 62 MALE 0 ABSENT PRESENT OLIGURIC PRESENT PRESENT ABSENT ABSENT ABSENT ABSENT DM 10 3.9
84 70 MALE 0 ABSENT ABSENT OLIGURIC PRESENT ABSENT ABSENT ABSENT ABSENT PRESENT DM 11 3.9
85 42 FEMALE 0 ABSENT PRESENT NON-OLIGURICPRESENT PRESENT ABSENT ABSENT ABSENT ABSENT ABSENT 9 2.3
86 53 FEMALE 0 ABSENT ABSENT OLIGURIC ABSENT PRESENT ABSENT ABSENT ABSENT ABSENT ABSENT 10.3 2.5
87 59 FEMALE 0 ABSENT PRESENT OLIGURIC PRESENT ABSENT ABSENT ABSENT ABSENT ABSENT DM 9 2.9
88 24 MALE 14 ABSENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 12.7 2.5
89 45 MALE 10 ABSENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT PRESENT ABSENT ABSENT 9.2 5.5
90 70 MALE 10 ABSENT PRESENT OLIGURIC ABSENT PRESENT ABSENT ABSENT PRESENT PRESENT CAD 12.8 5.1
91 56 FEMALE 12 ABSENT ABSENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT PRESENT DM 10.3 3.1
92 38 FEMALE 15 ABSENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 11 1.9
93 53 MALE 13 ABSENT ABSENT OLIGURIC PRESENT ABSENT PRESENT ABSENT ABSENT PRESENT ABSENT 8.4 9.8
94 19 MALE 0 ABSENT PRESENT OLIGURIC PRESENT ABSENT ABSENT ABSENT ABSENT PRESENT ABSENT 12.4 13.6
95 40 FEMALE 10 ABSENT PRESENT OLIGURIC PRESENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 9.5 4.8
96 32 MALE 0 ABSENT PRESENT NON-OLIGURICPRESENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 10.5 5.5
97 55 MALE 7 ABSENT ABSENT OLIGURIC ABSENT ABSENT PRESENT ABSENT ABSENT PRESENT ABSENT 12 3.6
98 60 MALE 8 ABSENT ABSENT OLIGURIC PRESENT ABSENT ABSENT ABSENT ABSENT PRESENT ABSENT 9.2 3.4
99 42 FEMALE 5 ABSENT PRESENT NON-OLIGURICABSENT ABSENT PRESENT ABSENT ABSENT ABSENT ABSENT 10 2.4
100 47 FEMALE 8 ABSENT PRESENT OLIGURIC PRESENT ABSENT PRESENT ABSENT ABSENT ABSENT ABSENT 12.4 4.5
101 19 MALE 21 ABSENT ABSENT OLIGURIC ABSENT ABSENT PRESENT ABSENT PRESENT PRESENT ABSENT 11.6 12
102 25 MALE 7 ABSENT ABSENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 7.2 3.2
103 29 MALE 9 ABSENT ABSENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 11.8 2.9
104 26 FEMALE 7 ABSENT ABSENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 10.5 2.4
105 64 MALE 15 ABSENT ABSENT OLIGURIC PRESENT ABSENT PRESENT PRESENT ABSENT ABSENT ABSENT 10.8 4.1
106 36 MALE 8 ABSENT PRESENT OLIGURIC ABSENT ABSENT ABSENT ABSENT PRESENT ABSENT ABSENT 11.7 3.6
107 45 FEMALE 0 PRESENT ABSENT OLIGURIC PRESENT PRESENT ABSENT ABSENT PRESENT PRESENT ABSENT 9.4 4.2
108 34 FEMALE 0 ABSENT ABSENT OLIGURIC PRESENT PRESENT PRESENT ABSENT PRESENT ABSENT ABSENT 13.6 4.5
109 23 FEMALE 22 ABSENT ABSENT OLIGURIC ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 11 1.9
110 29 FEMALE 18 ABSENT ABSENT NON-OLIGURICABSENT ABSENT ABSENT ABSENT ABSENT ABSENT ABSENT 10.8 2.2
111 35 FEMALE 18 ABSENT ABSENT OLIGURIC PRESENT PRESENT ABSENT ABSENT ABSENT PRESENT ABSENT 9.2 9.2
112 35 MALE 26 ABSENT ABSENT OLIGURIC ABSENT ABSENT ABSENT ABSENT PRESENT ABSENT ABSENT 10.2 16.2
urea aki rrt rrttype rrtfreq rrtind outcom findiag satgeFI
223 AT YES HD 2 SERUM CREATININE >4mg/dl CR ADD AKIN 3
112 AFTER YES PD 1 SYMPTOMATIC UREMIA CR ADD AKIN 3
131 AT YES PD 1 SYMPTOMATIC UREMIA CR ADD AKIN 3
293 AFTER YES HD 2 SYMPTOMATIC UREMIA IHM ADD AKIN 3
112 AT YES HD 2 SYMPTOMATIC UREMIA CR ADD AKIN 3
102 AT YES HD 2 SYMPTOMATIC UREMIA CR ADD AKIN 3
166 AT YES HD 3 SYMPTOMATIC UREMIA CR ADD AKIN 3
148 AT YES HD 2 SERUM CREATININE >4mg/dl CR ADD AKIN 3
131 AT YES HD 2 SERUM CREATININE >4mg/dl CR ADD AKIN 3
154 AFTER YES PD 1 SYMPTOMATIC UREMIA CR ADD AKIN 3
114 AT YES HD 2 SYMPTOMATIC UREMIA CR ADD AKIN 3
106 AT YES HD 2 SERUM CREATININE >4mg/dl CR ADD AKIN 3
120 AFTER YES PD 1 SYMPTOMATIC UREMIA CR ADD AKIN 3
115 AFTER NO NA NA NA CR ADD AKIN 1
47 AFTER NO NA NA NA CR ADD AKIN 1
56 AFTER NO NA NA NA CR ADD AKIN 2
70 AT NO NA NA NA CR ADD AKIN 1
176 AFTER NO NA NA NA CR ADD AKIN 3
90 AFTER NO NA NA NA CR ADD AKIN 3
94 AFTER NO NA NA NA CR ADD AKIN 2
115 AFTER NO NA NA NA CR ADD AKIN 2
55 AFTER NO NA NA NA CR ADD AKIN 1
110 AT NO NA NA NA CR ADD AKIN 1
56 AFTER NO NA NA NA CR ADD AKIN 2
78 AFTER NO NA NA NA CR ADD AKIN 2
76 AFTER NO NA NA NA CR ADD AKIN 1
88 AFTER NO NA NA NA CR ADD AKIN 3
70 AT NO NA NA NA CR ADD AKIN 1
67 AFTER NO NA NA NA CR ADD AKIN 1
68 AFTER NO NA NA NA CR ADD AKIN 3
67 AFTER NO NA NA NA CR ADD AKIN 2
52 AFTER NO NA NA NA CR ADD AKIN 1
45 AT NO NA NA NA CR ADD AKIN 1
67 AT NO NA NA NA CR ADD AKIN 2
82 AFTER NO NA NA NA CR ADD AKIN 2
56 AFTER NO NA NA NA CR ADD AKIN 1
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81 AT NO NA NA NA CR ADD AKIN 1
62 AFTER NO NA NA NA CR ADD AKIN 2
78 AFTER NO NA NA NA CR ADD AKIN 3
62 AFTER NO NA NA NA CR ADD AKIN 1
55 AT NO NA NA NA CR ADD AKIN 2
75 AFTER NO NA NA NA CR ADD AKIN 3
61 AFTER NO NA NA NA CR ADD AKIN 1
192 AT NO NA NA NA CR ADD AKIN 3
101 AT NO NA NA NA CR ADD AKIN 2
60 AFTER NO NA NA NA CR ADD AKIN 2
80 AFTER NO NA NA NA CR ADD AKIN 3
58 AT NO NA NA NA CR ADD AKIN 3
108 AT NO NA NA NA CR ADD AKIN 1
54 AFTER NO NA NA NA CR ADD AKIN 3
82 AFTER NO NA NA NA CR ADD AKIN 3
67 AFTER NO NA NA NA CR ADD AKIN 3
68 AT NO NA NA NA CR ADD AKIN 1
84 AFTER NO NA NA NA CR ADD AKIN 1
45 AT NO NA NA NA CR ADD AKIN 3
86 AFTER NO NA NA NA CR ADD AKIN 2
56 AT YES HD 6 SERUM CREATININE >4mg/dl CR Snake BIte AKIN 3
48 AFTER YES HD 3 SYMPTOMATIC UREMIA CR Snake BIte AKIN 3
56 AT YES PD 1 SYMPTOMATIC UREMIA CR Snake BIte AKIN 3
50 AFTER YES HD 3 SYMPTOMATIC UREMIA CR Snake BIte AKIN 3
164 AFTER YES HD 8 SERUM CREATININE >4mg/dl CR Snake BIte AKIN 3
150 AFTER YES HD 4 SYMPTOMATIC UREMIA CR Snake BIte AKIN 3
163 AT YES HD 5 SERUM CREATININE >4mg/dl CR Snake BIte AKIN 3
140 AFTER NO NA NA NA CR Snake BIte AKIN 1
66 AT NO NA NA NA CR Snake BIte AKIN 2
78 AFTER NO NA NA NA CR Snake BIte AKIN 3
69 AT NO NA NA NA CR Snake BIte AKIN 1
161 AFTER NO NA NA NA CR Snake BIte AKIN 3
50 AFTER NO NA NA NA CR Snake BIte AKIN 1
67 AFTER NO NA NA NA CR Snake BIte AKIN 1
56 AT NO NA NA NA CR Snake BIte AKIN 1
86 AFTER NO NA NA NA CR Snake BIte AKIN 1
150 AT YES HD 2 SERUM CREATININE >4mg/dl CR Snake BIte AKIN 3
120 AT YES HD 3 SERUM CREATININE >4mg/dl CR Snake BIte AKIN 3
140 AFTER YES HD 2 SYMPTOMATIC UREMIA CR Snake BIte AKIN 3
163 AT YES PD 1 SYMPTOMATIC UREMIA CR Snake BIte AKIN 3
68 AFTER NO NA NA NA CR Snake BIte AKIN 1
84 AFTER NO NA NA NA CR Snake BIte AKIN 3
86 AT NO NA NA NA CR Snake BIte AKIN 1
72 AFTER NO NA NA NA CR Snake BIte AKIN 2
108 AT YES HD 1 SYMPTOMATIC UREMIA IHM Sepsis AKIN 3
114 AT YES HD 1 SYMPTOMATIC UREMIA IHM Sepsis AKIN 3
98 AT YES PD 1 SYMPTOMATIC UREMIA IHM Sepsis AKIN 3
78 AT NO NA NA NA IHM Sepsis AKIN 3
54 AFTER NO NA NA NA IHM Sepsis AKIN 2
45 AFTER NO NA NA NA IHM Sepsis AKIN 2
84 AFTER NO NA NA NA IHM Sepsis AKIN 3
88 AT NO NA NA NA CR Sepsis AKIN 1
61 AT YES HD 2 SYMPTOMATIC UREMIA CR Sepsis AKIN 3
126 AT YES PD 1 SYMPTOMATIC UREMIA CR Sepsis AKIN 3
48 AT NO NA NA NA CR Sepsis AKIN 2
82 AFTER NO NA NA NA CR Sepsis AKIN 1
296 AT YES HD 5 SERUM CREATININE >4mg/dl CR TAFI AKIN 3
154 AFTER NO NA NA NA IHM TAFI AKIN 3
134 AFTER YES HD 2 SYMPTOMATIC UREMIA CR TAFI AKIN 3
58 AFTER NO NA NA NA IHM TAFI AKIN 3
83 AT NO NA NA NA CR TAFI AKIN 3
73 AFTER NO NA NA NA CR TAFI AKIN 2
96 AFTER NO NA NA NA CR TAFI AKIN 1
68 AT NO NA NA NA CR TAFI AKIN 3
199 AFTER YES HD 13 SYMPTOMATIC UREMIA PR AGN AKIN 3
98 AT NO NA NA NA CR AGN AKIN 2
80 AT NO NA NA NA CR AGN AKIN 1
89 AT NO NA NA NA CR AGN AKIN 1
68 AT NO NA NA NA CR NSAID Induced AKIN 3
135 AT NO NA NA NA CR Copper Sulfate Poisoning AKIN 2
67 AT NO NA NA NA IHM Copper Sulfate Poisoning AKIN 3
87 AFTER YES HD 1 SYMPTOMATIC UREMIA IHM Supervasmol Poisoning AKIN 3
66 AFTER NO NA NA NA CR Supervasmol Poisoning AKIN 1
69 AFTER NO NA NA NA CR Supervasmol Poisoning AKIN 1
108 AT YES HD 5 SYMPTOMATIC UREMIA CR Pigment Nephropathy AKIN 3
240 AFTER YES HD 11 SERUM CREATININE >4mg/dl PR Pigment Nephropathy AKIN 3
